A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 Multi-Phage Therapeutic in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection
Phase: PHASE2
Conditions: Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
Sponsor: Armata Pharmaceuticals, Inc.

CLINICAL STUDY PROTOCOL 
A Phase 2, Multi-Center, Double-Blind, Randomized, 
Placebo-Controlled Study to Evaluate the Safety, Phage Kinetics, 
and Efficacy of Inhaled AP-PA02 Multi-Phage Therapeutic in 
Subjects with Non-Cystic Fibrosis Bronchiectasis and Chronic 
Pulmonary Pseudomonas aeruginosa Infection 
Investigational Product: Anti-Pseudomonas aeruginosa Phage Product (AP-PA02) 
Protocol Number: AP-PA02-201 
EudraCT Number: 2021-006733-19 
Sponsor: 
Armata Pharmaceuticals, Inc. 
4503 Glencoe Avenue 
Marina del Rey, CA 90292 
United States 
Telephone: +1-310-665-2928 x207 
Version Number: 5.0 
Date: 19 December 2023 
Confidentiality Statement 
The information in this document is confidential and is not to be disclosed without the written 
consent of Armata Pharmaceuticals, Inc. except to the extent that disclosure would be required 
by law and for the purpose of evaluating and/or conducting a clinical study for Armata 
Pharmaceuticals, Inc. You are allowed to disclose the contents of this document only to your 
Institutional Review Board or Independent Ethics Committee and study personnel directly 
involved with conducting this Protocol. Persons to whom the information is disclosed must be 
informed that the information is confidential and proprietary to Armata Pharmaceuticals, Inc. and 
that it may not be further disclosed to third parties. 
NCT05616221

Annata Phannaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
SIGNATURE PAGE 
STUDY TITLE: A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled 
Study to Evaluate the Safety, Phage Kinetics, and Efficacy oflnhaled AP-PA02 
Multi-Phage Therapeutic in Subjects with Non-Cystic Fibrosis Bronchiectasis and Chronic 
Pulmonary Pseudomonas aeruginosa Infection 
We, the undersigned, have read this Protocol and agree that it contains all necessary information 
required to conduct the study. 
Armata Pharmaceuticals, Inc. 
Mina Pastagia, MD 
Chief Medical Officer 
Armata Pharmaceuticals, Inc. 
Confidential & Proprietary 
Version 5.0, 19 December 2023 
Date 
19Dec2023 
Page 2 of65 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 3 of 65 
Version 5.0, 19 December 2023 
INVESTIGATOR AGREEMENT 
By signing below, I agree that: 
I have read this Protocol. I approve this document and I agree that it contains all necessary details 
for carrying out the study as described. I will conduct this study in accordance with the design and 
specific provision of this Protocol and will make a reasonable effort to complete the study within 
the time designated. I will provide copies of this Protocol and access to all information furnished 
by Armata Pharmaceuticals, Inc. to study personnel under my supervision. I will discuss this 
material with them to ensure they are fully informed about the study product and study procedures. 
I will let them know that this information is confidential and proprietary to Armata 
Pharmaceuticals, Inc. and that it may not be further disclosed to third parties. I understand that the 
study may be terminated or enrollment suspended at any time by Armata Pharmaceuticals, Inc., 
with or without cause, or by me if it becomes necessary to protect the best interests of the study 
subjects. 
I agree to conduct this study in full accordance with Food and Drug Administration Regulations, 
Institutional Review Board/Ethics Committee Regulations and International Council for 
Harmonisation Guidelines for Good Clinical Practices. 
______________________________________________ 
____________________ 
Investigator’s Signature 
Date 
______________________________________________ 
Investigator’s Printed Name 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 4 of 65 
Version 5.0, 19 December 2023 
SYNOPSIS 
TITLE: A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study to 
Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 Multi-Phage Therapeutic 
in Subjects with Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas 
aeruginosa Infection 
PROTOCOL NUMBER: AP-PA02-201 
INVESTIGATIONAL PRODUCT: Anti-Pseudomonas aeruginosa Phage Product (AP-PA02) 
PHASE: 2 
INDICATION: Management of non-cystic fibrosis bronchiectasis (NCFB) subjects with chronic 
respiratory infections associated with P. aeruginosa  
OBJECTIVE: 
The primary objective is to evaluate the efficacy, safety, and phage kinetics of multiple inhaled 
doses of AP-PA02 administered as monotherapy and administered in combination with inhaled 
antibiotics compared to placebo and inhaled antibiotics alone. 
POPULATION: 
Inclusion criteria 
Subjects who meet all of the following criteria will be considered eligible for enrollment in the 
study: 
1. Are able and willing to comply with the Protocol and provide signed informed consent prior 
to any study-specific procedures;
2. Are male or female ≥18 years old;
3. Have a body mass index of ≥16.5 kg/m2;
4. Have findings consistent with bronchiectasis per computerized tomography (CT) (or 
high-resolution CT [HRCT]);
Note: A CT or HRCT that demonstrates the above criterion is required during Screening or 
the Screening Period unless such an examination has been performed within the last 5 years 
and meets the above criterion.
5. Have microbiological evidence of pulmonary P. aeruginosa infection from a sputum sample 
within the last 24 months. Sputum cultures may be repeated on up to 3 occasions during the 
Screening Period to document P. aeruginosa presence if the initial sputum culture is negative; 
6. Are willing and able to provide an induced sputum sample at Screening or during the 
Screening Period and at designated time points during the study and are willing and able to 
provide a spontaneously expectorated or induced sputum at all other time points;

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 5 of 65 
Version 5.0, 19 December 2023 
7. Have ≥104 colony-forming units of P. aeruginosa per gram of induced sputum obtained at 
Screening or during the Screening Period. Up to 3 specimens may be collected to meet this 
criterion;
8. Have forced expiratory volume (FEV1) ≥35% of predicted normal for age, gender, race, and 
height (using Global Lung Function Initiative standards) at Screening (regardless of the timing 
of the most recent prior administration of short-acting bronchodilator) or during the Screening 
Period;
9. Have, at the Baseline Visit, stable lung function, as determined by the Investigator, provided 
that the FEV1 at the Baseline Visit has not decreased by more than 10% compared to the FEV1 
measured at Screening or during the Screening Period;
10. Have no acute infection or exacerbation of primary disease, as determined by the Investigator, 
prior to randomization and first dose of study drug;
11. Are able to reproducibly perform spirometry per American Thoracic Society/European
Respiratory Society Standards;
12. Have past experience administering inhaled antibiotics and/or feel comfortable administering 
inhaled antibiotics and/or have a caregiver that is comfortable administering inhaled 
antibiotics to the subject;
13. For Cohort A, have not received chronic inhaled antipseudomonal antibiotic regimen for at 
least 3 months prior to Visit 1. For Cohort B, have received chronic inhaled antipseudomonal 
antibiotic regimen for at least 3 months prior to Visit 1;
14. Are able to comply with study visits and study procedures as judged by the Investigator;
15. Have a negative serum pregnancy test at Screening and a negative urine pregnancy test at the 
Baseline Visit, with results known prior to randomization and first dose of study drug, if a 
woman of childbearing potential;
16. Must agree to use a highly effective method of birth control (defined as those, alone or in 
combination, that result in a low failure rate [ie, less than 1% per year]) from Screening 
through 60 days following the last dose of study drug if female or female partner of male 
subjects, of childbearing potential; and
17. Must agree to use barrier contraception (ie, condoms) from Day 1 through 60 days following 
the last dose of study drug if male. Male subjects must refrain from donating sperm throughout 
the study and until 60 days after the last dose of study drug.
Exclusion criteria 
Subjects who meet any of the following criteria will not be eligible for enrollment in the study: 
1. Have previously received 1 or more doses of AP-PA02 in any context, including, but not 
limited to, prior participation in study AP-PA02-101, prior enrollment in this study, or 
emergency use (with or without prior authorization);
2. Have a history of lung transplantation;
3. Have a history of primary or acquired immunodeficiency syndromes, including, but not 
limited to, hypogammaglobulinemia and common variable immunodeficiency;

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 6 of 65 
Version 5.0, 19 December 2023 
4. Have a history of cystic fibrosis;
5. Have a history of α1-antitrypsin deficiency;
6. Have a history of pulmonary malignancy (primary or metastatic) or any other malignancy 
requiring treatment (including, but not limited to, chemotherapy, radiation therapy, or 
immunotherapy) within 1 year prior to Screening or anticipated during the study period 
(Exceptions: Basal cell carcinoma of the skin and carcinoma in situ of the cervix surgically 
excised and assessed as definitely removed);
7. Have, at Screening or during the Screening Period, either of the following findings:
o
A personal history or subject-reported family history of prolonged QT syndrome; or
o
Severe cardiovascular disease such as severe uncontrolled hypertension, unstable ischemic 
heart disease or cardiac arrhythmia and any other cardiac conditions that would confound 
the evaluation of safety in the opinion of the Investigator.
8. Have a history of hemoptysis meeting either of the following criteria:
o
Within the 6 months prior to Screening, was hospitalized for management or evaluation of 
hemoptysis; or
o
Within the 3 months prior to Screening, had hemoptysis totaling greater than 30 mL in a 
single day.
9. Have, within the 3 months prior to Screening, used supplemental oxygen during the day while 
at rest;
10. Have, within the 3 months prior to Screening, lost more than 10% of their body weight;
11. Have, within the 2 months prior to Screening, participated in any clinical study involving an 
investigational drug, an investigational device, or any systemic antibiotic;
Note: For systemic drugs or antibiotics with a half-life >12 days, the exclusion period is
5 half-lives.
12. Have, within the 30 days prior to Screening, received any intravenous, intramuscular, or oral 
antipseudomonal antibiotic (Exception: Chronic oral macrolide treatment with a stable dose is 
permitted);
Note: Inhaled antibiotic use for chronic suppression of P. aeruginosa is acceptable for subjects 
enrolling in Cohort B.
13. Have, within 30 days prior to Screening, had changes in either the treatment regimen or 
initiation of treatment with any of the following medications: oral macrolides (eg, 
azithromycin, erythromycin, or clarithromycin), hypertonic saline, mucolytics, bronchodilator 
medications, or oral corticosteroids;
14. Have, within the 30 days prior to Screening, received a course of any systemic antibiotics (by 
any route) for a new active infection at any site, unless assessed as fully resolved and not 
clinically significant by the Investigator with concurrence of the Medical Monitor;
15. Are, at Screening or during the Screening Period, receiving treatment for active pulmonary 
infection due to any of the following pathogens: nontuberculous mycobacteria, 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 7 of 65 
Version 5.0, 19 December 2023 
Staphylococcus aureus, Burkholderia cepacia complex, Aspergillus species, or endemic 
mycoses; 
16. Are receiving treatment for allergic bronchopulmonary aspergillosis;
17. Have, within 30 days prior to Screening, received either a systemic corticosteroid at a dose 
equivalent to >20 mg/day of prednisone (including every other day dosing of >40 mg 
equivalent) or any immunosuppressive medication or biologic for the treatment of 
inflammatory or autoimmune disease;
18. Have history of AIDS (human immunodeficiency virus positive with AIDS-defining condition 
and/or CD4 count <200 cells/mm3, and/or unstable detectable viral load) or chronic severe 
liver disease due to hepatitis B virus (HBV) or C virus (HCV) with liver biopsy or radiologic 
evidence of cirrhosis . If neither of these options are feasible to confirm disease status, 
ribonucleic acid testing should be performed by the Investigator at Screening;
19. Are, at Screening or during the Screening Period, breastfeeding or planning to become 
pregnant or breastfeed within the next 2 months;
20. Have, at Screening or during the Screening Period or at the Baseline Visit prior to 
randomization and first dose of study drug, vital signs considered to be clinically significant 
by the Investigator, endangering the safe participation of the subject in the study;
21. Have, at Screening or during the Screening Period, abnormal laboratory results. Subjects with 
values outside of the normal range may be permitted if the value is not clinically significant 
in the opinion of the Investigator with concurrence from the study Medical Monitor and/or 
Sponsor designee.
Note: Abnormal laboratory results may be repeated once and only once at the discretion of the 
Investigator.  
22. Have, in the opinion of the Investigator, any acute or chronic medical, psychiatric, or 
behavioral condition or laboratory abnormality such that any of the following apply: the 
subject is considered not medically stable or in any other way not suitable for the study; 
participation in the study is not in the subject’s best interest, including, but not limited to, 
concern that participation in the study has the potential to put the subject at undue risk or to 
interfere with the results of the study or the outcome measures.
STUDY DESIGN AND DURATION: 
This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the safety, 
tolerability, and efficacy of AP-PA02 administered by inhalation.  
The study will evaluate AP-PA02 administered by inhalation in medically stable NCFB subjects 
with chronic pulmonary P. aeruginosa infection at the time of Screening. A total of 24 eligible 
subjects who have not received antipseudomonal inhaled antibiotic for a minimum of 3 months 
prior to Visit 1 will be randomized to Cohort A to receive either AP-PA02 or placebo (2:1 ratio) 
administered via inhalation. A total of 24 eligible subjects who have received antipseudomonal 
inhaled antibiotic for a minimum of 3 months prior to Visit 1 will be randomized to Cohort B to 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 8 of 65 
Version 5.0, 19 December 2023 
receive either AP-PA02 plus their current antipseudomonal inhaled antibiotic or placebo plus their 
current antipseudomonal inhaled antibiotic (2:1 ratio) administered via inhalation. Cohort A and 
Cohort B will be run in parallel. Up to an additional 2 optional cohorts (up to 30 subjects in each 
cohort) may be included to evaluate different doses and durations of treatment after Data Safety 
Monitoring Board (DSMB) review. Prior to DSMB review, the maximum study treatment 
duration will be 10 days for Cohorts A and B and up to 28 days for the optional cohorts. 
For Cohort A, eligible subjects will be randomized at the Baseline Visit to receive 1 fractionated 
dose of AP-PA02 or placebo (1 dose distributed over 2 administrations given 6 hours apart on the 
same day on Day 1 and 10-12 hours apart each day on the remaining days) for 10 days (Study 
Days 1 through 10). Subjects will return to the clinic on Days 1, 5, and 10 (Visit 1/Day 1, Visit 
2/Day 5, and Visit 3/Day 10) of study drug dosing and approximately 24 hours post last AP-PA02 
or placebo dose for safety evaluations and phage recovery sampling, and again 7, 14, and 28 days 
after the last dose of AP-PA02 or placebo (Visit 4/Day 11, Visit 5/Day 17, Visit 6/Day 24, and 
Visit 7/Day 38). Subjects will be followed for safety for 4 weeks after the last dose of study drug. 
For Cohort B, eligible subjects will be randomized at the Baseline Visit to receive 1 fractionated 
dose of AP-PA02 or placebo (1 dose distributed over 2 administrations given 6 hours apart on the 
same day on Day 1 and 10-12 hours apart each day on the remaining days) for 10 days (Study 
Days 1 through 10) with their current inhaled antipseudomonal antibiotics administered for 28 
days (10 days of study drug treatment plus an additional 18 days). Subjects will return to the clinic 
on Days 1, 5, and 10 (Visit 1/Day 1, Visit 2/Day 5, and Visit 3/Day 10) of study drug dosing and 
approximately 24 hours post last AP-PA02 or placebo dose for safety evaluations and phage 
recovery sampling, and again 7, 14, and 28 days after the last dose of AP-PA02 or placebo (Visit 
4/Day 11, Visit 5/Day 17, Visit 6/Day 24, and Visit 7/Day 38). Subjects will be followed for 
safety for 4 weeks after the last dose of study drug.  
The first 2 subjects in Cohorts A and B will consist of 1 active and 1 placebo subject. Both subjects 
will be observed for at least 2 days after dosing, and if there are no Grade 2 or greater adverse 
events (AEs) assessed as treatment-related, dosing for the remaining subjects will proceed. 
Safety evaluations after the first dose for each cohort will include vital signs (blood pressure, HR, 
respiratory rate, and body temperature), SpO2, 12-lead ECG, and spirometry. The schedule of 
subsequent assessments during and after treatment is detailed in the Schedule of Assessments. 
Visit 7/Day 38 will be the End of Study (EOS) Visit. Safety and an anti-phage antibody titer will 
be performed at the EOS Visit 
Figure S1 displays the enrollment schematic. 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 9 of 65 
Version 5.0, 19 December 2023 
Figure S1. Enrollment Schematic: Parallel Design 
abx = antibiotic; BID = twice daily; EOS = End of Study; N = number of subjects; NCFB = non-cystic fibrosis bronchiectasis; P. 
aeruginosa = Pseudomonas aeruginosa. 
Safety Monitoring 
If subjects experience any acute AEs post-dose administration (regardless of causal relationship 
to study drug), the Investigator will determine if they may be observed in the clinic and discharged 
that day or, in consultation with the Medical Monitor, if they need to be admitted to the hospital 
for additional observation and/or treatment.  
All subjects will be followed for 28 days after the last dose of AP-PA02 or placebo for safety and 
phage recovery profile, or until resolution or stabilization of AEs or study-related AEs.  
AEs Grade 3 or higher assessed by the Investigator as related to study treatment will be reported 
to the Medical Monitor within 24 hours of awareness. The DSMB will constitute 3 independent 
physicians with experience in clinical studies and in the management of subjects with chronic 
pulmonary disease complicated by chronic infections. All DSMB procedures will be documented 
in a DSMB Charter which will be approved by all members and the Sponsor. The DSMB will 
conduct unblinded scheduled reviews of all available data after approximately 10% and/or after 
approximately 50% enrollment. They will also conduct ad hoc reviews as needed. Following each 
review, they will make recommendations regarding the conduct of the study, including, but not 
limited to, continuing as planned, modifying procedures, pausing enrollment and/or treatment 
pending additional information, and discontinuing the study. The planned dose levels and dosing 
duration after DSMB review may be modified and/or additional cohorts may be added based on 
emerging information from the current study as well as other ongoing studies. The highest total 
daily dose will not exceed 4 × 1012 PFU and dosing duration will not exceed 28 days. 
Cohort A 
NCFB + 
confirmed 
chronic PA 
infection 
(Not on 
chronic 
inhaled abx} 
Cohort B 
NCFB + 
confirmed 
chronic PA 
infection 
(On chronic 
inhaled abx) 
Study Day 
AP-PA02 bid x 
10 days (N=16) 
Pia ce bo bid X 
10 days (N=8) 
AP-PA02 bid x 
10 days+ SOC 
inhaled Abx x 
/ 
28 days (N=16) 
/
~~ 
SOC Inhaled 
Abx x 28 days 
(N=8) 
Study Drug Administration 
10 
Follow-up Visits: Days 5, 10, 11, 17, 24 
EOS Visit 
38 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 10 of 65 
Version 5.0, 19 December 2023 
DOSAGE FORMS AND ROUTE OF ADMINISTRATION: 
AP-PA02 is a proprietary multi-phage therapeutic candidate.
The AP-PA02 dose will be administered to each subject as 2 fractionated doses per treatment day. 
The dosages shown below are estimated (approximate) plaque-forming units (PFU): 
•
Each fractionated dose: 1.5 × 1011 PFU;
•
Total dose per treatment day: 3 × 1011 PFU; and
•
Total dose per 10-day treatment course: 3 × 1012 PFU.
AP-PA02 will be administered in the clinic
 during Visit 1/Day 1 (both doses), Visit 2/Day 5 (morning dose only), and Visit 3/Day 10 
(morning dose only). Subjects will administer AP-PA02 at home on all other treatment days. 
The placebo is 
. 
The placebo will be administered in the clinic/at home using the same fractionated dosing schedule 
and duration as AP-PA02 
. The placebo 
will be administered in the clinic during Visit 1/Day 1 (both doses), Visit 2/Day 5 (morning dose 
only), and Visit 3/Day 10 (morning dose only). Subjects will administer placebo at home on all 
other treatment days. 
On Visit 1/Day 1, clinic staff will administer the first dose of AP-PA02 or placebo. The subject 
and/or caregiver will administer the second dose of AP-PA02 or placebo with clinic staff 
observation after the subject has been trained on proper administration. Clinic staff will confirm 
the subject/caregiver is comfortable with administering AP-PA02 or placebo during this visit. If 
the subject is not comfortable administering AP-PA02 or placebo, the subject may visit the clinic 
for study drug administration until he/she or the caregiver is comfortable with proper study drug 
administration. 
Subjects in Cohort A will receive study treatment (AP-PA02 or placebo) administered as 1 dose 
distributed over 2 administrations given 6 hours apart on the same day on Day 1 and 10-12 hours 
apart each day on the remaining days for 10 consecutive days, with 28 days of follow-up after the 
last study drug dose. Subjects in Cohort B will receive study treatment (AP-PA02 or placebo) 
administered as 1 dose distributed over 2 administrations given 6 hours apart on the same day on 
Day 1 and 10-12 hours apart each day on the remaining days for 10 consecutive days plus their 
current antipseudomonal inhaled antibiotic for 28 days (10 days of study drug treatment plus an 
additional 18 days). Subjects in Cohort B will also have 28 days of follow-up after the last study 
drug dose. 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 11 of 65 
Version 5.0, 19 December 2023 
EFFICACY ENDPOINTS:  
The primary efficacy endpoint is sputum P. aeruginosa density as measured in sputum samples at 
1 week after end of treatment for study drug (Visit 5/Day 17). 
The phage recovery endpoint is based on AP-PA02 levels as measured in sputum and venous 
blood samples at time points specified in the Schedule of Assessments. 
The exploratory endpoints include the following: 
• Antipseudomonas antibiotic sensitivity of P. aeruginosa isolates at specified time points 
during the study; 
• Change in P. aeruginosa density from Baseline; 
• Change from Baseline of in vitro sensitivity of subject P. aeruginosa isolates to AP-PA02 
and/or individual phage components; 
• Change in spirometry from Baseline; 
• Change from Baseline levels of sputum neutrophil elastase; and 
• Change in quality of life as assessed by the following questionnaires: 
o Quality of Life-Bronchiectasis Questionnaire; 
o Leicester Cough Questionnaire; and 
o Saint George’s Respiratory Questionnaire. 
SAFETY VARIABLES: 
Safety will be assessed by monitoring AEs, vital signs, SpO2, laboratory data (chemistry, 
hematology, urinalysis, and coagulation), anti-phage antibody titer, 12-lead ECGs, spirometry, 
and physical examination findings. 
STATISTICAL ANALYSES: 
Analysis Populations 
Safety Population: The population for safety analyses will consist of all subjects who receive any 
AP-PA02 or placebo. 
Exploratory Efficacy Population: The population for efficacy (clinical activity) analysis will 
consist of all subjects who receive any AP-PA02 or placebo with at least 1 Baseline and 
1 post-Baseline assessment for the primary efficacy endpoint. 
Phage Distribution and Clearance Population: The population for phage distribution analyses will 
consist of all subjects who receive AP-PA02 and who have at least 1 detectable AP-PA02 
concentration measurement in sputum, blood, or urine samples. 
Efficacy Analyses 
The primary efficacy endpoint is the sputum P. aeruginosa density as measured in sputum samples 
at 1 week after end of treatment for study drug (Visit 5/Day 17). The primary efficacy endpoint 
will be analyzed as logarithmic colony-forming units/g sputum based on the Exploratory Efficacy 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 12 of 65 
Version 5.0, 19 December 2023 
Population, and the treatment groups will be compared using a 2-sample t test with 0.05 
significance level. 
In addition, descriptive statistics will be calculated for the primary efficacy endpoint and all the 
other efficacy endpoints by treatment group based on the Exploratory Efficacy Population. 
All statistical summaries will be descriptive in nature (eg, mean, standard deviation, median, 
minimum, and maximum for continuous variables and count and percentage for categorical 
variables). Further details, including the handling of missing data, will be specified in the 
Statistical Analysis Plan (SAP). The actual values and changes from Baseline will be summarized 
by visit using descriptive statistics, where appropriate, for all endpoints. Analysis details will be 
provided in the SAP. 
Safety Analyses 
Safety will be assessed by the incidence, severity, grade, and relationship of AEs, including 
clinically significant changes in vital signs, laboratory data, ECGs, and physical examinations. All 
safety evaluations will be conducted based on the Safety Population. 
Descriptive summaries will be provided by treatment group. 
SAMPLE SIZE DETERMINATION: 
The sample size was determined empirically to meet the objectives of the study. There is no formal 
power calculation for the sample size. A total of 24 eligible subjects will be randomized to 
Cohort A to receive either AP-PA02 or placebo (2:1 ratio) administered via inhalation. A total of 
24 eligible subjects will be randomized to Cohort B to receive either AP-PA02 plus their current 
antipseudomonal inhaled antibiotic or placebo plus their current antipseudomonal inhaled 
antibiotic (2:1 ratio) administered via inhalation. Up to an additional 2 optional cohorts (up to 
30 subjects in each cohort) may be included to evaluate different doses and durations of treatment 
after DSMB review. 
SITES: Approximately 30 sites globally 
SPONSOR: 
Armata Pharmaceuticals, Inc. 
4503 Glencoe Avenue 
Marina del Rey, CA 90292 
United States 
Telephone: +1-310-665-2928 x207 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 13 of 65 
Version 5.0, 19 December 2023 
TABLE OF CONTENTS 
Signature Page ................................................................................................................................ 2 
Investigator Agreement ................................................................................................................... 3 
Synopsis .......................................................................................................................................... 4 
Table of Contents .......................................................................................................................... 13 
List of Tables ................................................................................................................................ 17 
List of Figures ............................................................................................................................... 18 
List of Abbreviations and Definition of Terms............................................................................. 19 
1 Introduction and Background Information ............................................................................. 20 
1.1 
Introduction ................................................................................................................... 20 
1.1.1 Non-Cystic Fibrosis Bronchiectasis and Chronic Pseudomonas aeruginosa 
Infection ............................................................................................................ 20 
1.1.2 Phages as Antimicrobials .................................................................................. 20 
1.1.2.1 Mechanisms of Action of Phages ....................................................... 21 
1.2 
Rationale ........................................................................................................................ 21 
1.3 
Risk/Benefit ................................................................................................................... 22 
1.3.1 Study Benefits ................................................................................................... 22 
1.3.1.1 Known Benefits .................................................................................. 22 
1.3.1.2 Potential Benefits ................................................................................ 22 
1.3.2 Study Risks ........................................................................................................ 22 
1.3.2.1 Known Risks ....................................................................................... 22 
1.3.2.2 Potential Risks .................................................................................... 22 
2 Study Objective ....................................................................................................................... 23 
3 Study Description.................................................................................................................... 24 
3.1 
Summary of Study Design ............................................................................................ 24 
3.1.1 Safety Monitoring ............................................................................................. 25 
3.2 
Study Indication ............................................................................................................ 26 
4 Selection and Withdrawal of Subjects .................................................................................... 27 
4.1 
Inclusion Criteria ........................................................................................................... 27 
4.2 
Exclusion Criteria .......................................................................................................... 28 
4.3 
Stopping Criteria ........................................................................................................... 30 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 14 of 65 
Version 5.0, 19 December 2023 
4.3.1 Criteria for Potential Interruption or Discontinuation of Study Drug in 
Individual Subjects ............................................................................................ 30 
4.3.2 Criteria for Ad Hoc Data Safety Monitoring Board Review of Study .............. 31 
4.4 
Withdrawal or Modification of Individual Subject Study Participation ....................... 31 
4.4.1 Termination of the Study ................................................................................... 32 
5 Study Treatments .................................................................................................................... 33 
5.1 
Treatment Groups .......................................................................................................... 33 
5.2 
Rationale for Dosing ..................................................................................................... 33 
5.3 
Randomization and Blinding ......................................................................................... 33 
5.4 
Breaking the Blind ........................................................................................................ 34 
5.5 
Drug Supplies ................................................................................................................ 34 
5.5.1 Formulation and Packaging ............................................................................... 34 
5.5.2 Study Drug Preparation and Dispensing ........................................................... 35 
5.5.3 Study Drug Administration ............................................................................... 35 
5.5.4 Treatment Compliance ...................................................................................... 36 
5.5.5 Storage and Accountability ............................................................................... 36 
5.6 
Prior and Concomitant Medications and/or Procedures ................................................ 36 
5.6.1 Excluded Medications and/or Procedures ......................................................... 36 
5.6.2 Restricted Medications and/or Procedures ........................................................ 37 
5.6.3 Documentation of Prior and Concomitant Medication Use .............................. 37 
5.6.4 Contraception .................................................................................................... 37 
6 Study Procedures .................................................................................................................... 39 
7 Efficacy Assessments .............................................................................................................. 40 
7.1 
Efficacy Endpoints ........................................................................................................ 40 
7.2 
Sputum Culture ............................................................................................................. 40 
7.2.1 Antipseudomonal Antibiotic Sensitivity ........................................................... 41 
7.2.2 Sensitivity of Pseudomonas aeruginosa Isolates to AP-PA02 ......................... 41 
7.3 
Sputum Phage Titer ....................................................................................................... 41 
7.4 
Blood Phage Titer .......................................................................................................... 41 
7.5 
Urine Phage Titer .......................................................................................................... 41 
7.6 
Change in Spirometry .................................................................................................... 41 
7.7 
Daily Symptom Diary ................................................................................................... 41 
7.8 
Biomarkers .................................................................................................................... 42 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 15 of 65 
Version 5.0, 19 December 2023 
7.9 
Questionnaires ............................................................................................................... 42 
7.9.1 Quality of Life-Bronchiectasis Questionnaire ................................................... 42 
7.9.2 Leicester Cough Questionnaire ......................................................................... 42 
7.9.3 Saint George’s Respiratory Questionnaire ........................................................ 42 
8 Safety Assessments ................................................................................................................. 43 
8.1 
Adverse Events .............................................................................................................. 43 
8.1.1 Adverse (Drug) Reaction .................................................................................. 43 
8.1.2 Unexpected Adverse Drug Reaction ................................................................. 44 
8.1.3 Assessment of Adverse Events by the Investigator .......................................... 44 
8.2 
Serious Adverse Events ................................................................................................. 45 
8.3 
Serious Adverse Event Reporting − Procedures for Investigators ................................ 46 
8.4 
Pregnancy Reporting ..................................................................................................... 46 
8.5 
Expedited Reporting ...................................................................................................... 46 
8.6 
Special Situation Reports .............................................................................................. 47 
8.7 
Anti-Phage Antibody Titer ............................................................................................ 48 
8.8 
Spirometry ..................................................................................................................... 48 
8.9 
Oxygen Saturation ......................................................................................................... 48 
8.10 Clinical Laboratory Evaluations .................................................................................... 48 
8.11 Vital Signs ..................................................................................................................... 48 
8.12 Twelve-Lead Electrocardiograms ................................................................................. 48 
8.13 Physical Examinations .................................................................................................. 48 
8.14 Height and Weight ........................................................................................................ 49 
8.15 Pregnancy Testing ......................................................................................................... 49 
9 Statistics .................................................................................................................................. 50 
9.1 
Analysis Populations ..................................................................................................... 50 
9.2 
Statistical Methods ........................................................................................................ 50 
9.2.1 Analysis of Efficacy .......................................................................................... 50 
9.2.1.1 Efficacy Analyses ............................................................................... 50 
9.2.2 Analysis of Safety ............................................................................................. 50 
9.2.3 Interim Analysis ................................................................................................ 50 
9.2.4 Sample Size Determination ............................................................................... 51 
10 Data Management and Record Keeping ................................................................................. 52 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 16 of 65 
Version 5.0, 19 December 2023 
10.1 Data Management ......................................................................................................... 52 
10.1.1 Data Handling ................................................................................................... 52 
10.1.2 Computer Systems ............................................................................................. 52 
10.1.3 Data Entry ......................................................................................................... 52 
10.1.4 Medical Information Coding ............................................................................. 52 
10.1.5 Data Validation ................................................................................................. 52 
10.2 Record Keeping ............................................................................................................. 52 
10.3 End of Study .................................................................................................................. 53 
11 Investigator Requirements and Quality Control ..................................................................... 54 
11.1 Ethical Conduct of the Study ........................................................................................ 54 
11.2 Institutional Review Board/Independent Ethics Committee ......................................... 54 
11.3 Informed Consent .......................................................................................................... 54 
11.4 Subject Card .................................................................................................................. 55 
11.5 Study Monitoring Requirements ................................................................................... 55 
11.6 Disclosure of Data ......................................................................................................... 55 
11.7 Retention of Records ..................................................................................................... 55 
11.8 Publication Policy ......................................................................................................... 56 
11.9 Financial Disclosure ...................................................................................................... 56 
11.10 Insurance and Indemnity ............................................................................................... 56 
11.11 Legal Aspects ................................................................................................................ 56 
12 Study Administrative Information .......................................................................................... 57 
12.1 Protocol Amendments ................................................................................................... 57 
13 References ............................................................................................................................... 58 
Appendix A: Schedule of Assessments and Timing of Sample Collection and Procedures for 
the Treatment Period ............................................................................................................... 60 
Appendix B: Clinical Laboratory Analytes .................................................................................. 64 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 17 of 65 
Version 5.0, 19 December 2023 
LIST OF TABLES 
Table 1. 
Schedule of Assessments ............................................................................................ 60 
Table 2. 
Timing of Sample Collection and Procedures for the Treatment Period .................... 63 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 18 of 65 
Version 5.0, 19 December 2023 
LIST OF FIGURES 
Figure 1. Enrollment Schematic: Parallel Design ...................................................................... 25 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 19 of 65 
Version 5.0, 19 December 2023 
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS  
Abbreviation 
Definition 
AE 
Adverse event 
CF 
Cystic fibrosis 
CFR 
Code of Federal Regulations 
CRA 
Clinical Research Associate 
CT 
Computerized tomography 
CTA 
Clinical Trial Authorisation 
CTCAE 
Common Terminology Criteria for Adverse Events 
DSMB 
Data Safety Monitoring Board 
ECG 
Electrocardiogram 
eCRF 
Electronic case report form 
EDC 
Electronic data capture 
EIU 
Exposure In Utero 
EOS 
End of Study 
ET 
Early Termination 
FDA 
Food and Drug Administration 
FEF25-75 
Forced expiratory flow between 25% and 75% of the forced vital 
capacity 
FEV1 
Forced expiratory volume 
FVC 
Forced vital capacity 
GCP 
Good Clinical Practice 
GLI 
Global Lung Initiative 
HR 
Heart rate 
HRCT 
High-resolution computerized tomography 
ICF 
Informed consent form 
ICH 
International Council for Harmonisation 
IEC 
Independent Ethics Committee 
IRB 
Institutional Review Board 
LCQ 
Leicester Cough Questionnaire 
NCFB 
Non-cystic fibrosis bronchiectasis 
NIMP 
Non-investigational medicinal product 
PFU 
Plaque-forming units 
PRO 
Patient-reported outcome 
QOL-B 
Quality of Life-Bronchiectasis 
QTc 
Heart rate-corrected QT interval 
SAE 
Serious adverse event 
SAP 
Statistical Analysis Plan 
SpO2 
Oxygen saturation 
SUSAR 
Suspected Unexpected Serious Adverse Reaction 
ULN 
Upper limit of normal 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 20 of 65 
Version 5.0, 19 December 2023 
1 
INTRODUCTION AND BACKGROUND INFORMATION 
1.1 
Introduction 
Armata Pharmaceuticals, Inc. (Armata, the Sponsor) is developing a proprietary multi-phage 
therapeutic candidate (AP-PA02) for the management of non-cystic fibrosis bronchiectasis 
(NCFB) subjects with chronic respiratory infections associated with Pseudomonas aeruginosa. 
1.1.1 
Non-Cystic Fibrosis Bronchiectasis and Chronic Pseudomonas aeruginosa Infection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
1.1.2 
Phages as Antimicrobials 
 
 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 21 of 65 
Version 5.0, 19 December 2023 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1.2.1 
Mechanisms of Action of Phages 
 
 
 
1.2 
Rationale 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 22 of 65 
Version 5.0, 19 December 2023 
 
1.3 
Risk/Benefit 
1.3.1 
Study Benefits 
1.3.1.1 
Known Benefits 
The clinical benefit of AP-PA02 remains to be established. 
1.3.1.2 
Potential Benefits 
Subjects participating in this study will receive close medical attention and may have benefit 
regarding the clinical course of their chronic P. aeruginosa infection. Results from the proposed 
study may be useful in developing a new antimicrobial therapy for Pseudomonas infections that 
can be administered at home without the cost or logistical challenges posed by intravenous therapy 
or the collateral damage to the gut microbiota with systemic therapy. 
1.3.2 
Study Risks 
1.3.2.1 
Known Risks 
There is limited human experience with AP-PA02. No adverse drug reactions related to study drug 
have been identified so far. 
1.3.2.2 
Potential Risks 
All therapies have the potential to cause adverse experiences. The risks associated with blood 
sampling for safety or pharmacokinetic purposes are limited and the volume of blood needed is 
well below the acceptable limits for adults. Study intervention will be provided in addition to, not 
in replacement of, standard of care supportive and symptomatic therapy. 
The risks of nebulized phage therapy may include bronchial irritation and/or immune response to 
phages. As such, subjects will be monitored closely on Day 1 of dosing under clinical supervision 
with regularly scheduled vital sign, spirometry, and AE assessments. In addition, sentinel dosing, 
individual subject stopping criteria, and study stopping criteria are included as part of the study 
conduct. 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 23 of 65 
Version 5.0, 19 December 2023 
2 
STUDY OBJECTIVE 
The primary objective is to evaluate the efficacy, safety, and phage kinetics of multiple inhaled 
doses of AP-PA02 administered as monotherapy and administered in combination with inhaled 
antibiotics compared to placebo and inhaled antibiotics alone. 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 24 of 65 
Version 5.0, 19 December 2023 
3 
STUDY DESCRIPTION 
3.1 
Summary of Study Design 
This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the safety, 
tolerability, and efficacy of AP-PA02 administered by inhalation.  
The study will evaluate AP-PA02 administered by inhalation in medically stable NCFB subjects 
with chronic pulmonary P. aeruginosa infection at the time of Screening. A total of 24 eligible 
subjects who have not received an antipseudomonal inhaled antibiotic for a minimum of 3 months 
prior to Visit 1 will be randomized to Cohort A to receive either AP-PA02 or placebo (2:1 ratio) 
administered via inhalation. A total of 24 eligible subjects who have received an antipseudomonal 
inhaled antibiotic for a minimum of 3 months prior to Visit 1 will be randomized to Cohort B to 
receive either AP-PA02 plus their current antipseudomonal inhaled antibiotic or placebo plus their 
current antipseudomonal inhaled antibiotic (2:1 ratio) administered via inhalation. Cohort A and 
Cohort B will be run in parallel. Up to an additional 2 optional cohorts (up to 30 subjects in each 
cohort) may be included to evaluate different doses and durations of treatment after Data Safety 
Monitoring Board (DSMB) review. Prior to DSMB review, the maximum study treatment duration 
will be 10 days for Cohorts A and B and up to 28 days for the optional cohorts. 
For Cohort A, eligible subjects will be randomized at the Baseline Visit to receive 1 fractionated 
dose of AP-PA02 or placebo (1 dose distributed over 2 administrations given 6 hours apart on the 
same day on Day 1 and 10-12 hours apart each day on the remaining days) for 10 days (Study 
Days 1 through 10). Subjects will return to the clinic on Days 1, 5, and 10 (Visit 1/Day 1, Visit 
2/Day 5, and Visit 3/Day 10) of study drug dosing and approximately 24 hours post last AP-PA02 
or placebo dose for safety evaluations and phage recovery sampling, and again 7, 14, and 28 days 
after the last dose of AP-PA02 or placebo (Visit 4/Day 11, Visit 5/Day 17, Visit 6/Day 24, and 
Visit 7/Day 38). Subjects will be followed for safety for 4 weeks after the last dose of study drug.  
For Cohort B, eligible subjects will be randomized at the Baseline Visit to receive 1 fractionated 
dose of AP-PA02 or placebo (1 dose distributed over 2 administrations given 6 hours apart on the 
same day on Day 1 and 10-12 hours apart each day on the remaining days) for 10 days (Study 
Days 1 through 10) with their current inhaled antipseudomonal antibiotic administered for 28 days 
(10 days of study drug treatment plus an additional 18 days). Subjects will return to the clinic on 
Days 1, 5, and 10 (Visit 1/Day 1, Visit 2/Day 5, and Visit 3/Day 10) of study drug dosing and 
approximately 24 hours post last AP-PA02 or placebo dose for safety evaluations and phage 
recovery sampling, and again 7, 14, and 28 days after the last dose of AP-PA02 or placebo (Visit 
4/Day 11, Visit 5/Day 17, Visit 6/Day 24, and Visit 7/Day 38). Subjects will be followed for safety 
for 4 weeks after the last dose of study drug.  
The first 2 subjects in Cohorts A and B will consist of 1 active and 1 placebo subject. Both subjects 
will be observed for at least 2 days after dosing, and if there are no Grade 2 or greater AEs assessed 
as treatment-related, dosing for the remaining subjects will proceed. 
Safety evaluations after the first dose for each cohort will include vital signs (blood pressure, heart 
rate [HR], respiratory rate, and body temperature), oxygen saturation (SpO2), 12-lead 
electrocardiogram (ECG), and spirometry. The schedule of subsequent assessments during and 
after treatment is detailed in the Schedule of Assessments (Appendix A). 
Visit 7/Day 38 will be the End of Study (EOS) Visit. Safety and an anti-phage antibody titer will 
be performed at the EOS Visit. 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 25 of 65 
Version 5.0, 19 December 2023 
Figure 1 displays the enrollment schematic. 
Figure 1. Enrollment Schematic: Parallel Design 
 
 
 
abx = antibiotic; BID = twice daily; EOS = End of Study; N = number of subjects; NCFB = non-cystic fibrosis bronchiectasis; P. 
aeruginosa = Pseudomonas aeruginosa. 
 
3.1.1 
Safety Monitoring 
If subjects experience any acute AEs post-dose administration (regardless of causal relationship to 
study drug), the Investigator will determine if they may be observed in the clinic and discharged 
that day or, in consultation with the Medical Monitor, if they need to be admitted to the hospital 
for additional observation and/or treatment.  
All subjects will be followed for 28 days after the last dose of AP-PA02 or placebo for safety and 
phage recovery profile, or until resolution or stabilization of AEs or study-related AEs.  
AEs Grade 3 or higher assessed by the Investigator as related to study treatment will be reported 
to the Medical Monitor within 24 hours of awareness. The DSMB will constitute 3 independent 
physicians with experience in clinical studies and in the management of subjects with chronic 
pulmonary disease complicated by chronic infections. All DSMB procedures will be documented 
in a DSMB Charter which will be approved by all members and the Sponsor. The DSMB will 
conduct unblinded scheduled reviews of all available data after approximately 10% and/or after 
approximately 50% enrollment. They will also conduct ad hoc reviews as needed. Following each 
review, they will make recommendations regarding the conduct of the study, including, but not 
limited to, continuing as planned, modifying procedures, pausing enrollment and/or treatment 
pending additional information, and discontinuing the study. The planned dose levels and dosing 
duration after DSMB review may be modified and/or additional cohorts may be added based on 
Cohort A 
AP-PA02 bid x 
NCFB + 
10 days (N=16) 
confinned 
chronic PA 
infection 
(Not on 
Placebo bid x 
chronic 
10 days (N=8) 
inhaled abx} 
Follow-up Visits: Days 5, 10, 11, 17, 24 
AP-PA02 bid x 
Cohort B 
10 days+ SOC 
/ 
inhaled Abx x 
NCFB + 
28 days (N= 16) 
confim1ed 
chronic PA ~ 
SOC Inhaled 
infection 
Abx x 28 days 
(On chronic 
(N=8) 
inhaled abx) 
Study Drug Admin stration 
EOS Visit 
Study Day 
10 
38 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 26 of 65 
Version 5.0, 19 December 2023 
emerging information from the current study as well as other ongoing studies. The highest total 
daily dose will not exceed 4 × 1012 PFU and dosing duration will not exceed 28 days. 
3.2 
Study Indication 
The indication for this study is management of NCFB subjects with chronic respiratory infections 
associated with P. aeruginosa. 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 27 of 65 
Version 5.0, 19 December 2023 
4 
SELECTION AND WITHDRAWAL OF SUBJECTS  
4.1 
Inclusion Criteria 
Subjects who meet all of the following criteria will be considered eligible for enrollment in the 
study: 
1. Are able and willing to comply with the Protocol and provide signed informed consent prior 
to any study-specific procedures; 
2. Are male or female ≥18 years old; 
3. Have a body mass index of ≥16.5 kg/m2; 
4. Have findings consistent with bronchiectasis per computerized tomography (CT) (or 
high-resolution CT [HRCT]);  
Note: A CT or HRCT that demonstrates the above criterion is required during Screening or the 
Screening Period unless such an examination has been performed within the last 5 years and 
meets the above criterion. 
5. Have microbiological evidence of pulmonary P. aeruginosa infection from a sputum sample 
within the last 24 months. Sputum cultures may be repeated on up to 3 occasions during the 
Screening Period to document P. aeruginosa presence if the initial sputum culture is negative; 
6. Are willing and able to provide an induced sputum sample at Screening or during the Screening 
Period and at designated time points during the study and are willing and able to provide a 
spontaneously expectorated or induced sputum at all other time points; 
7. Have ≥104 colony-forming units of P. aeruginosa per gram of induced sputum obtained at 
Screening or during the Screening Period. Up to 3 specimens may be collected to meet this 
criterion; 
8. Have forced expiratory volume (FEV1) ≥35% of predicted normal for age, gender, race, and 
height (using Global Lung Function Initiative standards) at Screening (regardless of the timing 
of the most recent prior administration of short-acting bronchodilator) or during the Screening 
Period; 
9. Have, at the Baseline Visit, stable lung function, as determined by the Investigator, provided 
that the FEV1 at the Baseline Visit has not decreased by more than 10% compared to the FEV1 
measured at Screening or during the Screening Period; 
10. Have no acute infection or exacerbation of primary disease, as determined by the Investigator, 
prior to randomization and first dose of study drug; 
11. Are able to reproducibly perform spirometry per American Thoracic Society/European 
Respiratory Society Standards; 
12. Have past experience administering inhaled antibiotics and/or feel comfortable administering 
inhaled antibiotics and/or have a caregiver that is comfortable administering inhaled antibiotics 
to the subject; 
13. For Cohort A, have not received chronic inhaled antipseudomonal antibiotic regimen for at 
least 3 months prior to Visit 1. For Cohort B, have received chronic inhaled antipseudomonal 
antibiotic regimen for at least 3 months prior to Visit 1; 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 28 of 65 
Version 5.0, 19 December 2023 
14. Are able to comply with study visits and study procedures as judged by the Investigator;  
15. Have a negative serum pregnancy test at Screening and a negative urine pregnancy test at the 
Baseline Visit, with results known prior to randomization and first dose of study drug, if a 
woman of childbearing potential (as defined in Section 5.6.4); 
16. Must agree to use a highly effective method of birth control (defined as those, alone or in 
combination, that result in a low failure rate [ie, less than 1% per year]) from Screening through 
60 days following the last dose of study drug if female or female partner of male subjects, of 
childbearing potential; and 
17. Must agree to use barrier contraception (ie, condoms) from Day 1 through 60 days following 
the last dose of study drug if male. Male subjects must refrain from donating sperm throughout 
the study and until 60 days after the last dose of study drug. 
4.2 
Exclusion Criteria 
Subjects who meet any of the following criteria will not be eligible for enrollment in the study: 
1. Have previously received 1 or more doses of AP-PA02 in any context, including, but not 
limited to, prior participation in study AP-PA02-101, prior enrollment in this study, or 
emergency use (with or without prior authorization); 
2. Have a history of lung transplantation; 
3. Have a history of primary or acquired immunodeficiency syndromes, including, but not limited 
to, hypogammaglobulinemia and common variable immunodeficiency; 
4. Have a history of cystic fibrosis; 
5. Have a history of α1-antitrypsin deficiency; 
6. Have a history of pulmonary malignancy (primary or metastatic) or any other malignancy 
requiring treatment (including, but not limited to, chemotherapy, radiation therapy, or 
immunotherapy) within 1 year prior to Screening or anticipated during the study period 
(Exceptions: Basal cell carcinoma of the skin and carcinoma in situ of the cervix surgically 
excised and assessed as definitely removed); 
7. Have, at Screening or during the Screening Period, either of the following findings:  
o A personal history or subject-reported family history of prolonged QT syndrome; or 
o Severe cardiovascular disease such as severe uncontrolled hypertension, unstable ischemic 
heart disease or cardiac arrhythmia and any other cardiac conditions that would confound 
the evaluation of safety in the opinion of the Investigator. 
8. Have a history of hemoptysis meeting either of the following criteria:  
o Within the 6 months prior to Screening, was hospitalized for management or evaluation of 
hemoptysis; or 
o Within the 3 months prior to Screening, had hemoptysis totaling greater than 30 mL in a 
single day. 
9. Have, within the 3 months prior to Screening, used supplemental oxygen during the day while 
at rest; 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 29 of 65 
Version 5.0, 19 December 2023 
10. Have, within the 3 months prior to Screening, lost more than 10% of their body weight;  
11. Have, within the 2 months prior to Screening, participated in any clinical study involving an 
investigational drug, an investigational device, or any systemic antibiotic;  
Note: For systemic drugs or antibiotics with a half-life >12 days, the exclusion period is 
5 half-lives.  
12. Have, within the 30 days prior to Screening, received any intravenous, intramuscular, or oral 
antipseudomonal antibiotic (Exception: Chronic oral macrolide treatment with a stable dose is 
permitted); 
Note: Inhaled antibiotic use for chronic suppression of P. aeruginosa is acceptable for subjects 
enrolling in Cohort B. 
13. Have, within 30 days prior to Screening, had changes in either the treatment regimen or 
initiation of treatment with any of the following medications: oral macrolides (eg, 
azithromycin, erythromycin, or clarithromycin), hypertonic saline, mucolytics, bronchodilator 
medications, or oral corticosteroids; 
14. Have, within the 30 days prior to Screening, received a course of any systemic antibiotics (by 
any route) for a new active infection at any site, unless assessed as fully resolved and not 
clinically significant by the Investigator with concurrence of the Medical Monitor; 
15. Are, at Screening or during the Screening Period, receiving treatment for active pulmonary 
infection due to any of the following pathogens: nontuberculous mycobacteria, Staphylococcus 
aureus, Burkholderia cepacia complex, Aspergillus species, or endemic mycoses; 
16. Are receiving treatment for allergic bronchopulmonary aspergillosis; 
17. Have, within 30 days prior to Screening, received either a systemic corticosteroid at a dose 
equivalent to >20 mg/day of prednisone (including every other day dosing of >40 mg 
equivalent) or any immunosuppressive medication or biologic for the treatment of 
inflammatory or autoimmune disease; 
18. Have history of AIDS (human immunodeficiency virus positive with AIDS-defining condition 
and/or CD4 count <200 cells/mm3, and/or unstable detectable viral load) or chronic severe 
liver disease due to hepatitis B virus (HBV) or C virus (HCV) with liver biopsy or radiologic 
evidence of cirrhosis. If neither of these options are feasible to confirm disease status, 
ribonucleic acid testing should be performed by the Investigator at Screening; 
19. Are, at Screening or during the Screening Period, breastfeeding or planning to become 
pregnant or breastfeed within the next 2 months; 
20. Have, at Screening or during the Screening Period or at the Baseline Visit prior to 
randomization and first dose of study drug, vital signs considered to be clinically significant 
by the Investigator, endangering the safe participation of the subject in the study;  
21. Have, at Screening or during the Screening Period, abnormal laboratory results. Subjects with 
values outside of the normal range may be permitted if the value is not clinically significant in 
the opinion of the Investigator with concurrence from the study Medical Monitor and/or 
Sponsor designee.   
 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 30 of 65 
Version 5.0, 19 December 2023 
 
Note: Abnormal laboratory results may be repeated once and only once at the discretion of the 
Investigator.  
22. Have, in the opinion of the Investigator, any acute or chronic medical, psychiatric, or 
behavioral condition or laboratory abnormality such that any of the following apply: the subject 
is considered not medically stable or in any other way not suitable for the study; participation 
in the study is not in the subject’s best interest, including, but not limited to, concern that 
participation in the study has the potential to put the subject at undue risk or to interfere with 
the results of the study or the outcome measures. 
4.3 
Stopping Criteria 
The DSMB will oversee the safety and tolerability of AP-PA02 during the study and determine if 
it is acceptable to continue. However, safety and tolerability data will be reviewed on an ongoing 
basis by the Medical Monitor and stopping rules will be applicable starting with dosing of the first 
subject. 
4.3.1 
Criteria for Potential Interruption or Discontinuation of Study Drug in Individual 
Subjects 
In the event that any of the following criteria are encountered, the Investigator will review the AE 
with the Medical Monitor as soon as feasible. The Investigator will hold the next administration 
pending that review. The Investigator and Medical Monitor in consultation with the Sponsor will 
decide whether to continue to hold study treatment pending additional information or to 
discontinue study treatment. 
• ≥Grade 3 AE or laboratory abnormality per Common Terminology Criteria for AEs (CTCAE) 
version 5.0 considered attributable to AP-PA02 (confirmed by unblinding). If the event or 
laboratory test is not listed in the CTCAE, the event or laboratory test should be graded by 
applying the CTCAE guidelines detailed in Section 8.1.3; 
Note: Clinically significant laboratory abnormalities classified per above should be confirmed 
with a repeat test within 24 hours. 
• Any serious AE (SAE) considered attributable to AP-PA02 (confirmed by unblinding); or 
• Acute bronchospasm, defined as a decrease in absolute FEV1 of ≥15% accompanied by 
symptoms requiring medical intervention, occurring from the Baseline value up to 4 hours 
following study drug administration and persisting following administration of a short-acting 
bronchodilator. 
Any subject who prematurely discontinues from study drug, will have documented the reason and 
date of discontinuation in the electronic case report form (eCRF) and the subject should be 
encouraged to continue to complete all safety and key efficacy assessments at subsequent study 
visits. For subjects who do not agree to participate in subsequent study visits, study staff should 
make every effort to complete the full panel of assessments scheduled for the Early Termination 
(ET) Visit.  

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 31 of 65 
Version 5.0, 19 December 2023 
4.3.2 
Criteria for Ad Hoc Data Safety Monitoring Board Review of Study 
In the event that any of the following criteria are encountered, the DSMB may, as described in the 
DSMB Charter, convene to review available data and make recommendations, including but not 
limited to, if the cohort should stop or if it is necessary to pause the study, enrollment, or treatment 
and/or make recommendations to modify the Protocol (ie, decrease or change the dose of study 
drug, modify safety monitoring): 
• If any unacceptable toxicity (as determined by the Investigator or Sponsor’s Medical Monitor) 
occurs; 
• If ≥1 SAE considered attributable to AP-PA02 (confirmed by unblinding) occurs; or 
• If ≥2 of all treated subjects experience similar SAEs or Grade 3 (CTCAE version 5.0) 
considered attributable to AP-PA02 (confirmed by unblinding). 
Note: All ≥Grade 3 (CTCAE version 5.0) laboratory abnormalities should be confirmed with 
a repeat test within 24 hours. 
If the DSMB recommends, and the Sponsor then implements, stopping study treatment and, 
subsequently, the Sponsor, independent of or following a DSMB recommendation, proposes to 
restart the study, a substantial amendment will be submitted to regulatory agencies and 
Institutional Review Boards (IRBs)/Independent Ethics Committees (IECs). The study will not 
restart until the amendment has been approved by regulatory agencies and IRBs/IECs. These 
requirements are not applicable if the Sponsor pre-emptively pauses study treatment for subject 
safety pending DSMB review and the DSMB recommends resuming study treatments and/or any 
study modifications recommended do not represent substantial Protocol changes. 
4.4 
Withdrawal or Modification of Individual Subject Study Participation 
Participation of a subject in this clinical study will be discontinued for any of the following reasons: 
• The subject or legally authorized representative withdraws consent or requests discontinuation 
from the study for any reason; 
• The subject becomes pregnant; or 
• The subject has not demonstrated to clinic staff that he/she can properly administer study drug, 
the subject has no appropriate caregiver who has demonstrated that he/she can properly 
administer study drug to the subject, or the subject is not able or willing to return to the clinic 
for study drug administration to ensure that the subject properly receives study drug as per the 
Protocol. 
The Investigator may, with concurrence of the Medical Monitor or Sponsor, discontinue or modify 
a subject’s study participation for any of the following reasons:  
• Occurrence of any AE (whether or not attributed to study treatment), medical condition, or 
circumstance that does not allow the subject to adhere to the requirements of the Protocol or 
continued participation is not in the best interest of the subject; or 
• Subject failure to comply with Protocol requirements or study-related procedures. 
Subjects will be considered lost to follow-up if, after completing study treatment, they fail to attend 
a required visit or are unresponsive despite 3 attempts to reach them by telephone, text message, 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 32 of 65 
Version 5.0, 19 December 2023 
email, and/or regular postal mail. Such subjects may, with the concurrence of the Sponsor, be 
terminated from study participation and notification sent by registered mail to the last known 
address. These contact attempts will be documented in both the study record and the subject’s 
medical record. 
Subjects who discontinue prematurely from the study or whose participation is modified will be 
strongly encouraged to complete the full panel of safety assessments scheduled for the ET Visit. 
The reason for subject withdrawal must be documented in the eCRF. 
Withdrawn or lost to follow-up subjects may be replaced to ensure adequate numbers of evaluable 
subjects at the discretion of the Sponsor. Subjects who discontinue for study drug-related safety or 
tolerability reasons will not be replaced. 
4.4.1 
Termination of the Study 
The Sponsor may terminate the study at any time and for any reason, including, but not limited to, 
recommendation by the DSMB, new nonclinical information regarding the study treatment, or if 
required by regulatory authorities. 
Depending on the circumstances, termination procedures may or may not include completion of 
study treatment as assigned for all subjects who have received at least 1 dose. After a subject 
receives their last treatment, all EOS treatment safety evaluations will be completed. 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 33 of 65 
Version 5.0, 19 December 2023 
5 
STUDY TREATMENTS 
5.1 
Treatment Groups 
Cohort A subjects will receive AP-PA02 or placebo. Cohort B subjects will receive AP-PA02 plus 
their current antipseudomonal inhaled antibiotic or placebo plus their current antipseudomonal 
inhaled antibiotic. See Figure 1 for the enrollment schematic. 
5.2 
Rationale for Dosing 
 
  
 
  
  
 
  
 
 
 
 
 
 
  
 
 
 
  
 
  
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3 
Randomization and Blinding 
A total of 24 eligible subjects will be randomized to Cohort A to receive either AP-PA02 or 
placebo (2:1 ratio) administered via inhalation. A total of 24 eligible subjects will be randomized 
to Cohort B to receive either AP-PA02 plus their current antipseudomonal inhaled antibiotic or 
placebo plus their current antipseudomonal inhaled antibiotic (2:1 ratio) administered via 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 34 of 65 
Version 5.0, 19 December 2023 
inhalation. Up to an additional 2 optional cohorts (up to 30 subjects in each cohort) may be 
included to evaluate different doses and durations of treatment after DSMB review. 
This is a double-blind study. All subjects, Investigators, and study and Sponsor personnel involved 
in the conduct of the study will be blinded to subject treatment assignment. There will be a 
designated unblinded statistician who will generate and have access to the randomization code. 
The unblinded statistician and other personnel who may become unblinded will not otherwise 
participate in any study procedures. 
5.4 
Breaking the Blind 
Unblinding at the request of the Investigator should occur only in the event of a severe AE or SAE 
that is reasonably assessed as treatment related and for which it is necessary to know the treatment 
assignment to determine an appropriate course of therapy for the subject. If the Investigator must 
identify the treatment assignment of an individual subject, the Investigator or qualified designee 
should request the treatment assignment from the centralized randomization system. They should 
not attempt to get this information from the site’s unblinded study team. The Investigator is advised 
to not reveal the treatment assignment to any other site, Sponsor, or Contract Research 
Organization personnel. 
Whenever possible, prior to proceeding with unblinding, the Investigator will contact the Sponsor 
to discuss the need to break the blind. The Investigator will notify the Sponsor as soon as is 
practical in the event of the study blind being broken and will document the reason. In the event 
this is not possible, the Investigator should contact the Sponsor as soon as possible to discuss the 
event without revealing the treatment assignment. The Investigator must document the subject 
identification, the date and time of breaking the blind, and must clearly explain the reasons for 
breaking the blind. 
Medically necessary care should not be delayed for unblinding information (ie, the Investigator 
should treat the subject based on the subject’s signs/symptoms without waiting for the unblinding 
process to be completed). 
Subjects who are unblinded and discontinue study drug should continue to complete all safety 
assessments at subsequent study visits. 
5.5 
Drug Supplies 
5.5.1 
Formulation and Packaging 
 
 
 
 
 
 
 
  

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 35 of 65 
Version 5.0, 19 December 2023 
5.5.2 
Study Drug Preparation and Dispensing 
 
 
 
 
 
 
 
 
 
 
. 
Study drug will be administered in the clinic by qualified site personnel/at home by the subject via 
the designated study nebulizer, until all study drug solution has been administered. 
 
 
 
 The subject and/or subject’s caregiver will be trained on administration of study drug for 
administration at home. The subject will receive study drug doses for home administration on 
Visit 1/Day 1 for treatment Days 2 through 4 and on Visit 2/Day 5 for treatment Days 5 (second 
dose) through 9, and on Visit 3/Day 10 for treatment Day 10 (second dose). 
 
 
 
5.5.3 
Study Drug Administration 
The AP-PA02 dose will be administered to each subject as 2 fractionated doses per treatment day. 
The dosages shown below are estimated (approximate) PFU: 
• Each fractionated dose: 1.5 × 1011 PFU; 
• Total dose per treatment day: 3 × 1011 PFU; and 
• Total dose per 10-day treatment course: 3 × 1012 PFU. 
AP-PA02 will be administered in the clinic 
 
during Visit 1/Day 1 (both doses), Visit 2/Day 5 (morning dose only), and Visit 3/Day 10 (morning 
dose only). Subjects will administer AP-PA02 at home on all other treatment days. 
The placebo will be administered in the clinic/at home using the same fractionated dosing schedule 
and duration as AP-PA02 and 
. The placebo 
will be administered in the clinic during Visit 1/Day 1 (both doses), Visit 2/Day 5 (morning dose 
only), and Visit 3/Day 10 (morning dose only). Subjects will administer placebo at home on all 
other treatment days. 
On Visit 1/Day 1, clinic staff will administer the first dose of AP-PA02 or placebo. The subject 
and/or caregiver will administer the second dose of AP-PA02 or placebo with clinic staff 
observation after the subject has been trained on proper administration. Clinic staff will confirm 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 36 of 65 
Version 5.0, 19 December 2023 
the subject/caregiver is comfortable with administering AP-PA02 or placebo during this visit. If 
the subject is not comfortable administering AP-PA02 or placebo, the subject may visit the clinic 
for study drug administration until he/she or the caregiver is comfortable with proper study drug 
administration. 
Subjects in Cohort A will receive study treatment (AP-PA02 or placebo) administered as 1 dose 
distributed over 2 administrations given 6 hours apart on the same day on Day 1 and 10-12 hours 
apart each day on the remaining days on 10 consecutive days, with 28 days of follow-up after the 
last study drug dose. Subjects in Cohort B will receive study treatment (AP-PA02 or placebo) 
administered as 1 dose distributed over 2 administrations given 6 hours apart on the same day on 
Day 1 and 10-12 hours apart each day on the remaining days for 10 consecutive days plus their 
current antipseudomonal inhaled antibiotic for 28 days (10 days of study drug treatment plus an 
additional 18 days). Subjects in Cohort B will also have 28 days of follow-up after the last study 
drug dose. 
5.5.4 
Treatment Compliance 
Details of the date and time when the study drug is administered, along with any deviation from 
the procedure described in this Protocol, will be recorded in the subject’s source documents and 
the eCRF for the days study drug is administered in the clinic. For the days subjects administer 
study drug at home, treatment compliance will be documented in a subject diary and will be 
assessed by the diary entries, including date, times, and whether the complete dose was 
administered, and returned study drug. 
5.5.5 
Storage and Accountability 
. 
The Investigator must designate a research pharmacist or other staff member to be unblinded and 
maintain an inventory record of drugs received and dispensed. Used vials should be retained for 
drug accountability by the site monitor, unless prohibited by local procedures, in which case an 
alternative drug accountability process will be agreed upon with the Sponsor. Additional details 
on study drug handling will be provided in the Pharmacy Manual. 
Forms will be provided to facilitate the inventory control. These forms must be used unless the 
Investigator has previously established a system that complies with local regulations and is 
approved by the Sponsor. The study drug must be dispensed only at the institution(s) specified on 
form Food and Drug Administration (FDA) 1572. 
Upon completion or termination of the study and after inventory by a Sponsor-designated monitor, 
it will be determined if unopened drug is to be sent to the Sponsor in the original containers or is 
to be destroyed on site. Residual solutions must be discarded after use, as outlined in the Pharmacy 
Manual and per approved institutional procedures. 
5.6 
Prior and Concomitant Medications and/or Procedures 
5.6.1 
Excluded Medications and/or Procedures 
Systemic corticosteroids at a dose equivalent to >20 mg/day of prednisone (including every other 
day dosing of >40 mg equivalent) or any immunosuppressive medication or biologic for the 
treatment of inflammatory or autoimmune disease is prohibited. 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 37 of 65 
Version 5.0, 19 December 2023 
5.6.2 
Restricted Medications and/or Procedures 
Subjects may continue on an oral macrolide treatment (eg, azithromycin, erythromycin, or 
clarithromycin), hyper tonic saline, mucolytics, bronchodilator medications, or oral corticosteroids 
with a stable dose as long as it was not initiated within the 30 days prior to Screening. 
5.6.3 
Documentation of Prior and Concomitant Medication Use 
Medications used within 30 days prior to Screening will be recorded. The coronavirus disease 2019 
vaccination status (including type of vaccine and administration date[s]) of all subjects will be 
recorded as a prior (if received prior to dosing) and/or concomitant medication in the eCRF. 
Any treatment given in addition to the study drug during the study will be regarded as a 
concomitant medication and must be recorded on the appropriate eCRF. 
Any relevant medications received in the 28 days prior to randomization must be recorded on the 
appropriate eCRF, along with the reason for use, dates of administration, and dosages. 
Concomitant medications, including over-the-counter medications and herbal supplements, should 
be kept to a minimum during the study. However, if these are considered necessary for the subject’s 
welfare and are unlikely to interfere with the study drug, they may be given at the discretion of the 
Investigator and recorded in the subject’s source documents and the eCRF. 
5.6.4 
Contraception 
Women of childbearing potential must agree to use a highly effective method of birth control from 
the list below (defined as those, alone or in combination, that result in a low failure rate, ie, less 
than 1% per year when used consistently and correctly). Double barrier methods (a combination 
of condom with cap, diaphragm, or sponge with spermicide) are not considered highly effective. 
Childbearing potential is defined as being fertile following menarche and until becoming 
post-menopausal, unless permanently sterile. Permanent sterilization methods include 
hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. 
Highly effective methods of birth control include: 
• Combined (estrogen and progesterone containing) hormonal contraception associated with 
inhibition of ovulation (oral, intravaginal, transdermal); 
• Progesterone-only hormonal contraception associated with inhibition of ovulation (oral, 
injectable, implantable); 
• Intrauterine device; 
• Intrauterine hormone-releasing system; 
• Bilateral tubal occlusion; 
• Vasectomized partner (provided that partner is the sole sexual partner and has received medical 
assessment of the surgical success); and 
• Sexual abstinence. Sexual abstinence must be true abstinence which is the preferred and usual 
lifestyle of the subject. Periodic abstinence (eg, calendar, ovulation, symptom-thermal, 
post-ovulation methods), declaration of abstinence for the duration of the study, and 
withdrawal are not acceptable methods of contraception. 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 38 of 65 
Version 5.0, 19 December 2023 
Birth control measures must be employed during the time of participation (beginning at the 
Screening Visit) in this study. Protections against pregnancy must be continued for at least 60 days 
after the last dose of study drug. 
A man is considered fertile after puberty unless permanently sterile by bilateral orchiectomy. Male 
subjects with medical confirmation of azoospermia and/or infertility will be considered 
permanently sterile. A man who is fertile should use a condom during treatment and until 60 days 
after the last dose of study drug. Male subjects must refrain from donating sperm throughout the 
study and until 60 days after the last dose of study drug. 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 39 of 65 
Version 5.0, 19 December 2023 
6 
STUDY PROCEDURES 
Study procedures will follow the Schedule of Assessments and Timing of Sample Collection and 
Procedures for the Treatment Period (Appendix A). 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 40 of 65 
Version 5.0, 19 December 2023 
7 
EFFICACY ASSESSMENTS 
7.1 
Efficacy Endpoints 
The primary efficacy endpoint is sputum P. aeruginosa density as measured in sputum samples at 
1 week after end of treatment for study drug (Visit 5/Day 17). 
The phage recovery endpoint is based on AP-PA02 levels as measured in sputum and venous blood 
samples at time points specified in the Schedule of Assessments (Appendix A). 
The exploratory endpoints include the following: 
• Antipseudomonas antibiotic sensitivity of P. aeruginosa isolates at specified time points 
during the study; 
• Change in P. aeruginosa density from Baseline; 
• Change from Baseline of in vitro sensitivity of subject P. aeruginosa isolates to AP-PA02 
and/or individual phage components; 
• Change in spirometry from Baseline; 
• Change from Baseline levels of sputum neutrophil elastase; and 
• Change in quality of life as assessed by the following questionnaires: 
o Quality of Life-Bronchiectasis (QOL-B) Questionnaire; 
o Leicester Cough Questionnaire (LCQ); and 
o Saint George’s Respiratory Questionnaire. 
7.2 
Sputum Culture 
Sputum for microbiology will be processed at a central laboratory for all visits. Quantitative 
cultures and sensitivity will be performed. P. aeruginosa isolates obtained from sputum samples 
at all visits will be frozen for possible future genotyping analysis. No subject (human) samples 
will be retained for any genetic analysis. 
Collection of sputum via spontaneous expectoration or induction will be performed per 
standardized methodology at the time points specified in the Schedule of Assessments and Timing 
of Sample Collection and Procedures for the Treatment Period (Appendix A). Induced sputum 
samples for culture will be required at Screening, Baseline, Visit 2/Day 5, Visit 3/Day 10, Visit 4/ 
Day 11, Visit 5/Day 17, Visit 6/Day 24, and Visit 7/EOS/Day 38. Standardized sputum induction 
methodology will be detailed in the Study Manual.  
For expectorated sputum collection, subjects may be asked to provide first morning samples 
expectorated before a given clinic visit or the subjects may provide the expectorated sputum 
sample during the clinic visit. Samples collected at home by the subject should ideally be collected 
prior to administration of any inhaled antipseudomonal antibiotic. Subjects will be provided 
sputum collection containers and insulated transport containers in which to carry their specimens 
to the clinic. 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 41 of 65 
Version 5.0, 19 December 2023 
7.2.1 
Antipseudomonal Antibiotic Sensitivity 
Antipseudomonal antibiotic sensitivity will be tested by the central microbiology laboratory at the 
visits indicated in the Schedule of Assessments (Appendix A). 
7.2.2 
Sensitivity of Pseudomonas aeruginosa Isolates to AP-PA02 
The change in P. aeruginosa isolate sensitivity to AP-PA02 between initiation of study drug and 
the last isolation of P. aeruginosa from sputum will be assessed as indicated in the Schedule of 
Assessments (Appendix A). 
7.3 
Sputum Phage Titer 
Sputum for phage titer will be obtained as designated in the Schedule of Assessments and Timing 
of Sample Collection and Procedures for the Treatment Period (Appendix A). Induced sputum 
samples will be required on Visit 1/Day 1, Visit 2/Day 5, Visit 3/Day 10, Visit 4/Day 11, 
Visit 5/Day 17, Visit 6/Day 24, and Visit 7/EOS/Day 38. Sputum samples will be obtained in the 
morning on Visit 4/Day 11. 
7.4 
Blood Phage Titer 
Blood for phage titer will be obtained as designated in the Schedule of Assessments and Timing 
of Sample Collection and Procedures for the Treatment Period (Appendix A). When blood samples 
are scheduled at time points when safety laboratories and phage titer samples are also to be 
collected, safety laboratory samples are to be collected first, followed by phage titer samples. 
Blood samples will be obtained in the morning on Visit 4/Day 11.  
7.5 
Urine Phage Titer 
Urine samples for phage recovery will be obtained at the visits indicated in the Schedule of 
Assessments (Appendix A) using provided collection containers. Date and time will be recorded 
for each urine sample collection at the designated time points. 
7.6 
Change in Spirometry 
Spirometry will be performed per American Thoracic Society/European Respiratory Society 
Standards28,29,30,31,32 and evaluated locally at the clinical study site. FEV1, forced vital capacity 
(FVC), and forced expiratory flow between 25% and 75% of the FVC (FEF25-75) will be collected. 
Actual liter values will be recorded. Details regarding spirometry procedures and standards will 
be included in the Study Manual. 
7.7 
Daily Symptom Diary 
A standardized subject diary will be provided to each study subject to collect subject symptoms 
following the administration of study drug. Solicited symptoms assessed may include but are not 
limited to: difficulty breathing, cough, sputum production, color of sputum, hemoptysis, feeling 
feverish, and/or fatigue. The daily diary will be dispensed to study subjects starting at the 
Baseline Visit for all subjects. Subjects will be instructed to bring the diary to the clinic for each 
subsequent study visit for review and the diary will be collected at the End of Study Visit.  

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 42 of 65 
Version 5.0, 19 December 2023 
7.8 
Biomarkers 
Biomarkers, including sputum neutrophil elastase, will be tested by the central laboratory as 
indicated in the Schedule of Assessments and Timing of Sample Collection and Procedures for the 
Treatment Period (Appendix A). 
7.9 
Questionnaires 
Subjects will complete questionnaires according to the Schedule of Assessments (Appendix A). 
7.9.1 
Quality of Life-Bronchiectasis Questionnaire 
The QOL-B Questionnaire is a self-administered PRO measure designed specifically for subjects 
with bronchiectasis.33 This PRO contains 37 items on 8 scales to assess respiratory symptoms, 
functioning, and health-related quality of life of subjects within the past week. 
7.9.2 
Leicester Cough Questionnaire 
The LCQ is a 19 item self-completed quality of life measure of chronic cough which is responsive 
to change.34 Subjects will respond to each item using a 7-point Likert response scale. 
7.9.3 
Saint George’s Respiratory Questionnaire 
The Saint George’s Respiratory Questionnaire is a measure to assess impaired health and perceived 
well-being (quality of life).35 The Saint George’s Respiratory Questionnaire was designed to allow 
for comparative measurements of health and quantify changes in health following treatment. 
Scores of 3 components (symptoms, activity, and impacts [on daily life]) and total score will be 
evaluated.36 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 43 of 65 
Version 5.0, 19 December 2023 
8 
SAFETY ASSESSMENTS 
8.1 
Adverse Events 
An AE is defined as any untoward medical occurrence in a clinical investigation subject 
administered a pharmaceutical product, which does not necessarily have a causal relationship with 
this treatment. An AE can therefore be any unfavorable and/or unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of an 
investigational medicinal product, whether or not related to the investigational medicinal product. 
All AEs, including observed or volunteered problems, complaints, or symptoms, are to be recorded 
on the appropriate eCRF. 
AEs, which include clinical laboratory test variables, will be monitored and documented from the 
time of first dose of AP-PA02 or placebo until the EOS Visit. Subjects should be instructed to 
report any AE that they experience to the Investigator, whether or not they think the event is due 
to study treatment. Beginning at the date of the first dose of study drug, Investigators should make 
an assessment for AEs at each visit and record the event on the appropriate AE eCRF. 
Wherever possible, a specific disease or syndrome rather than individual associated signs and 
symptoms should be identified by the Investigator and recorded on the eCRF. However, if an 
observed or reported sign or symptom is not considered a component of a specific disease or 
syndrome by the Investigator, it should be recorded as a separate AE on the eCRF. Additionally, 
the condition that led to a medical or surgical procedure (eg, surgery, endoscopy, tooth extraction, 
or transfusion) should be recorded as an AE, not the procedure itself.  
Any medical condition already present prior to the first dose of the study drug should be recorded 
as medical history and not be reported as an AE unless the medical condition or signs or symptoms 
present at Baseline changes in severity, frequency, or seriousness at any time during the study. In 
this case, it should be reported as an AE. 
Clinically significant abnormal laboratory or other examination (eg, ECG) findings that are 
detected during the study or are present prior to the first dose of study drug and significantly 
worsen during the study should be reported as AEs, as described below. The Investigator will 
exercise his or her medical and scientific judgment in deciding whether an abnormal laboratory 
finding or other abnormal assessment is clinically significant. Clinically significant abnormal 
laboratory values occurring during the clinical study will be followed until repeat tests return to 
normal, stabilize, or are no longer clinically significant. Abnormal test results that are determined 
to be an error should not be reported as an AE. Laboratory abnormalities or other abnormal clinical 
findings (eg, ECG abnormalities) should be reported as an AE if any of the following are 
applicable: 
• If an intervention is required as a result of the abnormality; 
• If action taken with the study drug is required as a result of the abnormality; or 
• Based on the clinical judgment of the Investigator. 
8.1.1 
Adverse (Drug) Reaction 
All noxious and unintended responses to a medicinal product related to any dose should be 
considered an adverse drug reaction. “Responses” to a medicinal product means that a causal 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 44 of 65 
Version 5.0, 19 December 2023 
relationship between a medicinal product and an AE is at least a reasonable possibility, ie the 
relationship cannot be ruled out. 
8.1.2 
Unexpected Adverse Drug Reaction 
An unexpected adverse drug reaction is defined as an adverse reaction, the nature or severity of 
which is not consistent with the applicable product information. For AP-PA02, the reference safety 
information is included in the Investigator’s Brochure currently in force. The reference safety 
information will be reviewed yearly, and the periodicity of the review will be harmonized with the 
reporting period of the Development Safety Update Report. 
8.1.3 
Assessment of Adverse Events by the Investigator 
The severity of all AEs should be graded according to the CTCAE version 5.0. For those AE terms 
not listed in the CTCAE, the following grading system should be used: 
• CTCAE Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations 
only; intervention not indicated; 
• CTCAE Grade 2: Moderate; minimal local or noninvasive intervention indicated; limiting 
age-appropriate instrumental activities of daily living; 
• CTCAE Grade 3: Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care 
activities of daily living; 
• CTCAE Grade 4: Life-threatening consequences; urgent intervention indicated; or 
• CTCAE Grade 5: Death related to the AE. 
Causality assessment 
The relationship of an AE to the administration of the study drug is to be assessed according to the 
following definitions: 
No (unrelated, not related, unlikely to be related) – The time course between the administration of 
study drug and the occurrence or worsening of the AE rules out a causal relationship and another 
cause (concomitant drugs, therapies, complications, etc) is suspected. 
Yes (possibly, probably, or definitely related) – The time course between the administration of 
study drug and the occurrence or worsening of the AE is consistent with a causal relationship and 
no other cause (concomitant drugs, therapies, complications, etc) can be identified. 
The definition implies a reasonable possibility of a causal relationship between the event and the 
study drug. This means that there are facts (evidence) or arguments to suggest a causal relationship. 
 
The following factors should also be considered: 
• The temporal sequence from study drug administration- 
The event should occur after the study drug is given. The length of time from study drug 
exposure to event should be evaluated in the clinical context of the event. 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 45 of 65 
Version 5.0, 19 December 2023 
• Underlying, concomitant, intercurrent diseases- 
Each report should be evaluated in the context of the natural history and course of the disease 
being treated and any other disease the subject may have. 
• Concomitant drug- 
The other drugs the subject is taking or the treatment the subject receives should be examined 
to determine whether any of them might be recognized to cause the event in question. 
• Known response pattern for this class of study drug- 
Clinical and/or preclinical data may indicate whether a particular response is likely to be a 
class effect. 
• Exposure to physical and/or mental stresses- 
The exposure to stress might induce adverse changes in the recipient and provide a logical and 
better explanation for the event. 
• The pharmacology and pharmacokinetics of the study drug- 
The known pharmacologic properties (absorption, distribution, metabolism, and excretion) of 
the study drug should be considered. 
8.2 
Serious Adverse Events 
An AE or adverse reaction is considered serious if, in the view of either the Investigator or Sponsor, 
it results in any of the following outcomes: 
• Death; 
• A life-threatening AE; 
Note: An AE or adverse reaction is considered “life-threatening” if, in view of either the 
Investigator or Sponsor, its occurrence places the subject at immediate risk of death. It does 
not include an event that, had it occurred in a more severe form, might have caused death. 
• Requires hospitalization or prolongation of existing hospitalizations; 
Note: Any hospital admission with at least 1 overnight stay will be considered an inpatient 
hospitalization. An emergency room or urgent care visit without hospital admission will not 
be recorded as an SAE under this criterion, nor will hospitalization for a procedure scheduled 
or planned before signing of informed consent, or elective treatment of a pre-existing condition 
that did not worsen from Baseline. However, unexpected complications and/or prolongation 
of hospitalization that occur during elective surgery should be recorded as AEs and assessed 
for seriousness. Admission to the hospital for social or situational reasons (ie, no place to stay, 
live too far away to come for hospital visits, respite care) will not be considered inpatient 
hospitalizations.  
• A persistent or significant disability/incapacity or substantial disruption of the ability to 
conduct normal life functions; 
• A congenital anomaly/birth defect; or 
• An important medical event. 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 46 of 65 
Version 5.0, 19 December 2023 
Note: Important medical events that do not meet any of the above criteria may be considered 
an SAE when, based upon appropriate medical judgment, they may jeopardize the subject and 
may require medical or surgical intervention to prevent one of the outcomes listed above. 
Examples of such medical events include allergic bronchospasm requiring intensive treatment 
in an emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospitalizations, or the development of drug dependency/drug abuse. 
8.3 
Serious Adverse Event Reporting − Procedures for Investigators 
Initial Reports 
All SAEs occurring from the time of informed consent until 30 days following the last 
administration of study drug must be reported to the Sponsor/designee within 24 hours of the 
knowledge of the occurrence. After the 30-day reporting window, any SAE that the Investigator 
considers related to study drug must be reported to the Sponsor/designee. Instructions for the 
reporting of SAEs are outlined in the study reference instructions provided to the Investigator. 
Follow-up Reports 
The Investigator must continue to follow the subject until the SAE has subsided or until the 
condition becomes chronic in nature, stabilizes (in the case of persistent impairment), or the subject 
dies. 
Within 24 hours of receipt of follow-up information, the Investigator must update the SAE form 
and submit any supporting documentation (eg, subject discharge summary or autopsy reports). 
8.4 
Pregnancy Reporting 
If a subject becomes pregnant during the study or within the safety follow-up period defined in the 
Protocol, the Investigator is to stop dosing with study drug(s) immediately and the subject should 
be withdrawn from the study. Early termination procedures should be implemented at that time.  
A pregnancy is not considered to be an AE or SAE; however, it must be reported to the 
Sponsor/designee within 24 hours of knowledge of the event.   
If the female partner of a male subject becomes pregnant while the subject is receiving study drug 
or within the safety follow-up period defined in the Protocol, the Investigator should notify the 
Sponsor/designee as described above.  
The pregnancy should be followed until the outcome of the pregnancy, whenever possible. Once 
the outcome of the pregnancy is known, the Investigator will report the information to the 
Sponsor/designee. If the outcome of the pregnancy meets the criteria for immediate classification 
as an SAE (ie, postpartum complication, spontaneous abortion, stillbirth, neonatal death, or 
congenital anomaly), the Investigator should follow the procedures for reporting an SAE. 
8.5 
Expedited Reporting 
The Sponsor/designee will report all relevant information about Suspected Unexpected Serious 
Adverse Reactions (SUSARs) that are fatal or life-threatening as soon as possible to the FDA, 
applicable competent authorities in all the Member States concerned, and to the Central Ethics 
Committee, and in any case no later than 7 days after knowledge by the Sponsor/designee of such 
a case. Relevant follow-up information will subsequently be communicated within an additional 
8 days.  

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 47 of 65 
Version 5.0, 19 December 2023 
All other SUSARs will be reported to the FDA, applicable competent authorities concerned, and 
to the Central Ethics Committee concerned as soon as possible but within a maximum of 15 days 
of first knowledge by the Sponsor/designee.  
The Sponsor/designee will also report any additional expedited safety reports required in 
accordance with the timelines outlined in country-specific legislation.  
The Sponsor/designee will also inform all Investigators as required per local regulation. 
The requirements above refer to the requirements relating to investigational medicinal products. 
Expedited reporting of SUSARs related to comparators is also required in line with the 
requirements above. Expedited reporting of SUSARs related to non-investigational medicinal 
products (NIMPs) (and any other NIMPs) is not required. Listings of cases related to NIMPs will 
be included in the Development Safety Update Report. 
8.6 
Special Situation Reports 
Special situation reports include reports of overdose, misuse, abuse, medication error, and reports 
of adverse reactions associated with product complaints. 
• Overdose: Refers to the administration of a quantity of a medicinal product given per 
administration or cumulatively (accidentally or intentionally), which is above the maximum 
recommended dose according to the Protocol. Clinical judgement should always be applied. In 
cases of a discrepancy in the drug accountability, overdose will be established only when it is 
clear that the subject has taken additional dose(s), or the Investigator has reason to suspect that 
the subject has taken additional dose(s).  
• Misuse: Refers to situations where the medicinal product is intentionally and inappropriately 
used in a way that is not in accordance with the Protocol instructions or local prescribing 
information and may be accompanied by harmful physical and/or psychological effects.  
• Abuse: Is defined as persistent or sporadic, intentional excessive use of a medicinal product, 
which is accompanied by harmful physical or psychological effects. 
• Medication error: Is any unintentional error in the prescribing, dispensing, or administration 
of a medicinal product by a healthcare professional, subject, or consumer, respectively. The 
administration or consumption of the unassigned treatment and administration of an expired 
product are always reportable as medication errors. Cases of subjects missing doses of 
investigational product are not considered reportable as medication errors. 
• Product complaint: Is defined as any written, electronic, or oral communication that alleges 
deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or 
performance of a drug or device after it is released for distribution. A special situation report 
form will only be completed if a complaint is associated with an adverse drug reaction.  
All special situation events as described above must be reported to the Sponsor/designee within 
24 hours of knowledge of the event. All AEs associated with these special situation reports should 
be reported as AEs or SAEs as well as recorded on the AE eCRF and/or the SAE report form. 
Details of the symptoms and signs, clinical management, and outcome should be provided, when 
available. 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 48 of 65 
Version 5.0, 19 December 2023 
8.7 
Anti-Phage Antibody Titer 
The anti-phage antibody titer will be assessed as indicated in the Schedule of Assessments 
(Appendix A). 
8.8 
Spirometry 
Spirometry will be performed per American Thoracic Society/European Respiratory Society 
Standards28,29,30,31,32 and evaluated locally at the clinical study site. FEV1, FVC, and FEF25-75 will 
be collected. Actual liter values will be recorded. Details regarding spirometry procedures and 
standards will be included in the Study Manual. Study eligibility will be based on percent predicted 
value using Global Lung Initiative (GLI) standards, which requires race and ethnicity information 
as part of the GLI calculation. Spirometry will be assessed according to the Schedule of 
Assessments and Timing of Sample Collection and Procedures for the Treatment Period 
(Appendix A). Spirometry will be collected prior to sputum induction on non-Treatment Period 
Visits. 
8.9 
Oxygen Saturation 
SpO2 will be assessed according to the Schedule of Assessments and Timing of Sample Collection 
and Procedures for the Treatment Period (Appendix A). 
8.10 
Clinical Laboratory Evaluations 
Clinical laboratory evaluations include chemistry, hematology, urinalysis, and coagulation and 
will be assessed according to the Schedule of Assessments and Timing of Sample Collection and 
Procedures for the Treatment Period (Appendix A). See Appendix B for a list of clinical laboratory 
analytes. 
Abnormal laboratory results may be repeated once and only once at the discretion of the 
Investigator. Subjects with values outside the normal range may be permitted if the value is not 
clinically significant in the opinion of the Investigator with concurrence from the study Medical 
Monitor and/or Sponsor designee. 
8.11 
Vital Signs 
Vital signs include blood pressure, HR, respiratory rate, and body temperature and will be assessed 
according to the Schedule of Assessments and Timing of Sample Collection and Procedures for 
the Treatment Period (Appendix A).  
8.12 
Twelve-Lead Electrocardiograms 
Twelve-lead ECGs will be performed according to the Schedule of Assessments and Timing of 
Sample Collection and Procedures for the Treatment Period (Appendix A). The Fridericia formula 
for calculating QTc will be used. 
8.13 
Physical Examinations 
A full physical examination will be performed at the Screening Visit, Baseline Visit, and the EOS 
Visit. A symptom-directed physical examination will be performed at the other visits according to 
the Schedule of Assessments (Appendix A). 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 49 of 65 
Version 5.0, 19 December 2023 
8.14 
Height and Weight 
Height and weight will be collected according to the Schedule of Assessments (Appendix A). 
Height will be collected at the Screening Visit only and will be used to calculate body mass index 
and percent predicted spirometry values by GLI standards. 
8.15 
Pregnancy Testing 
For women of childbearing potential only, a serum pregnancy test will be performed during the 
Screening Period and a urine pregnancy test will be performed at the other visits as indicated in 
the Schedule of Assessments (Appendix A). 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 50 of 65 
Version 5.0, 19 December 2023 
9 
STATISTICS 
9.1 
Analysis Populations 
Safety Population: The population for safety analyses will consist of all subjects who receive any 
AP-PA02 or placebo. 
Exploratory Efficacy Population: The population for efficacy (clinical activity) analysis will 
consist of all subjects who receive any AP-PA02 or placebo with at least 1 Baseline and 
1 post-Baseline assessment for the primary efficacy endpoint. 
Phage Distribution and Clearance Population: The population for phage distribution analyses will 
consist of all subjects who receive AP-PA02 and who have at least 1 detectable AP-PA02 
concentration measurement in sputum, blood, or urine samples. 
9.2 
Statistical Methods 
9.2.1 
Analysis of Efficacy 
9.2.1.1 
Efficacy Analyses 
The primary efficacy endpoint is the sputum P. aeruginosa density as measured in sputum samples 
at 1 week after end of treatment for study drug (Visit 5/Day 17). The primary efficacy endpoint 
will be analyzed as logarithmic colony-forming units/g sputum based on the Exploratory Efficacy 
Population, and the treatment groups will be compared using a 2-sample t test with 
0.05 significance level. 
In addition, descriptive statistics will be calculated for the primary efficacy endpoint and all the 
other efficacy endpoints by treatment group based on the Exploratory Efficacy Population. 
All statistical summaries will be descriptive in nature (eg, mean, standard deviation, median, 
minimum, and maximum for continuous variables and count and percentage for categorical 
variables). Further details, including the handling of missing data, will be specified in the 
Statistical Analysis Plan (SAP). The actual values and changes from Baseline will be summarized 
by visit using descriptive statistics, where appropriate, for all endpoints. Analysis details will be 
provided in the SAP. 
9.2.2 
Analysis of Safety 
Safety will be assessed by the incidence, severity, grade, and relationship of AEs, including 
clinically significant changes in vital signs, laboratory data, ECGs, and physical examinations. All 
safety evaluations will be conducted based on the Safety Population. 
Descriptive summaries will be provided by treatment group. 
9.2.3 
Interim Analysis 
No formal interim analysis is planned for the study. 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 51 of 65 
Version 5.0, 19 December 2023 
9.2.4 
Sample Size Determination 
The sample size was determined empirically to meet the objectives of the study. There is no formal 
power calculation for the sample size. A total of 24 eligible subjects will be randomized to 
Cohort A to receive either AP-PA02 or placebo (2:1 ratio) administered via inhalation. A total of 
24 eligible subjects will be randomized to Cohort B to receive either AP-PA02 plus their current 
antipseudomonal inhaled antibiotic or placebo plus their current antipseudomonal inhaled 
antibiotic (2:1 ratio) administered via inhalation. Up to an additional 2 optional cohorts (up to 
30 subjects in each cohort) may be included to evaluate different doses and durations of treatment 
after DSMB review. 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 52 of 65 
Version 5.0, 19 December 2023 
10 
DATA MANAGEMENT AND RECORD KEEPING 
10.1 
Data Management 
10.1.1 
Data Handling 
Data will be recorded at the site on eCRFs and reviewed by the Clinical Research Associate (CRA) 
during monitoring visits. The CRAs will verify data recorded in the EDC system with source 
documents. All corrections or changes made to any study data must be appropriately tracked in an 
audit trail in the EDC system. An eCRF will be considered complete when all missing, incorrect, 
and/or inconsistent data have been accounted for. 
10.1.2 
Computer Systems 
Data will be processed using a validated computer system conforming to regulatory requirements. 
10.1.3 
Data Entry 
Data must be recorded using the EDC system as the study is in progress. All site personnel must 
log into the system using their secure username and password in order to enter, review, or correct 
study data. These procedures must comply with Title 21 of the Code of Federal Regulations (CFR) 
(21 CFR Part 11) and other appropriate international regulations. All passwords will be strictly 
confidential. 
10.1.4 
Medical Information Coding 
For medical information, the following thesauri will be used: 
• Medical Dictionary for Regulatory Activities (latest) for medical history and AEs; and 
• World Health Organization Drug Dictionary for prior and concomitant medications. 
10.1.5 
Data Validation 
Validation checks programmed within the EDC system, as well as supplemental validation 
performed via review of the downloaded data, will be applied to the data in order to ensure 
accurate, consistent, and reliable data. Data identified as erroneous, or data that are missing, will 
be referred to the investigative site for resolution through data queries. 
The eCRFs must be reviewed and electronically signed by the Investigator. 
10.2 
Record Keeping 
Records of subjects, source documents, monitoring visit logs, eCRFs, inventory of study product, 
regulatory documents, and other Sponsor correspondence pertaining to the study must be kept in 
the appropriate study files at the site. Source data are defined as all information in original records 
and certified copies of original records of clinical findings, observations, or other activities in a 
clinical study necessary for the evaluation and reconstruction of the clinical study. Source data are 
contained in source documents (original records or certified copies). These records will be retained 
in a secure file for the period as set forth in the Clinical Study Agreement. Prior to transfer or 
destruction of these records, the Sponsor must be notified in writing and be given the opportunity 
to further store such records.  

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 53 of 65 
Version 5.0, 19 December 2023 
10.3 
End of Study 
The EOS (“study completion”) is defined as the date of the last Protocol-specified visit/assessment 
(including telephone contact) for the last subject in the study. Subjects alive at the EOS who require 
further follow-up may be entered into a separate long-term follow-up study. 
 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 54 of 65 
Version 5.0, 19 December 2023 
11 
INVESTIGATOR REQUIREMENTS AND QUALITY CONTROL  
11.1 
Ethical Conduct of the Study 
Good Clinical Practice (GCP) is an international ethical and scientific quality standard for 
designing, conducting, recording, and reporting studies that involve human subjects. Compliance 
with this standard provides public assurance that the rights, safety, and well-being of study subjects 
are protected, consistent with the principles that have their origin in the Declaration of Helsinki, 
and that the clinical study data are credible. 
11.2 
Institutional Review Board/Independent Ethics Committee 
The IRB/IEC will review all appropriate study documentation in order to safeguard the rights, 
safety, and well-being of subjects. The study will only be conducted at sites where IRB/IEC 
approval has been obtained. The Protocol, Investigator’s Brochure, informed consent form (ICF), 
advertisements (if applicable), written information given to the subjects, safety updates, annual 
progress reports, and any revisions to these documents will be provided to the IRB by the 
Investigator. 
Federal regulations and International Council for Harmonisation (ICH) Guidelines require that 
approval be obtained from an IRB/IEC prior to participation of subjects in research studies. Prior 
to study onset, the Protocol, any Protocol Amendments, ICFs, advertisements to be used for subject 
recruitment, and any other written information regarding this study to be provided to a subject or 
subject’s legal guardian must be approved by the IRB/IEC. 
No drug will be released to the site for dosing until written IRB/IEC authorization has been 
received by the Sponsor. 
It is the responsibility of the Sponsor or their designee to obtain the approval of the responsible 
ethics committees according to the national regulations.  
The study will only start in the respective sites once the respective committee’s written approval 
has been given. 
11.3 
Informed Consent 
The ICF and any changes to the ICF made during the course of the study must be agreed to by the 
Sponsor or designee and the IRB prior to its use and must be in compliance with all ICH GCP, 
local regulatory requirements, and legal requirements. 
The Investigator must ensure that each study subject is fully informed about the nature and 
objectives of the study and possible risks associated with participation and must ensure that the 
subject has been informed of his/her rights to privacy. The Investigator will obtain written 
informed consent from each subject before any study-specific activity is performed and should 
document in the source documentation that consent was obtained prior to enrollment in the study. 
The original signed copy of the ICF must be maintained by the Investigator and is subject to 
inspection by a representative of the Sponsor, auditors, the IRB, and/or regulatory agencies. A 
copy of the signed ICF will be given to the subject. 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 55 of 65 
Version 5.0, 19 December 2023 
11.4 
Subject Card  
On enrollment in the study, the subject will receive a subject card to be carried at all times. The 
subject card will state that the subject is participating in a clinical research study, type of treatment, 
number of treatment packs received, and contact details in case of an SAE. 
11.5 
Study Monitoring Requirements 
It is the responsibility of the Investigator to ensure that the study is conducted in accordance with 
the Protocol, ICH GCP, Directive 2001/20/EC, applicable regulatory requirements, and the 
Declaration of Helsinki and that valid data are entered into the eCRFs. 
To achieve this objective, the CRA’s duties are to aid the Investigator and, at the same time, the 
Sponsor in the maintenance of complete, legible, well-organized, and easily retrievable data. 
Before the enrollment of any subject in this study, the Sponsor or their designee will review with 
the Investigator and site personnel the following documents: Protocol, Investigator’s Brochure, 
eCRFs and procedures for their completion, informed consent process, and the procedure for 
reporting SAEs. 
The Investigator will permit the Sponsor or their designee to monitor the study as frequently as 
deemed necessary to determine that data recording and Protocol adherence are satisfactory. During 
the monitoring visits, information recorded on the eCRFs will be verified against source 
documents and requests for clarification or correction may be made. After the eCRF data are 
entered by the site, the CRA will review the data for safety information, completeness, accuracy, 
and logical consistency. Computer programs that identify data inconsistencies may be used to help 
monitor the clinical study. If necessary, requests for clarification or correction will be sent to 
Investigators. The Investigator and his/her staff will be expected to cooperate with the CRA and 
provide any missing information, whenever possible. 
All monitoring activities will be reported and archived. In addition, monitoring visits will be 
documented at the investigational site by signature and date on the study-specific monitoring log. 
11.6 
Disclosure of Data 
Data generated by this study must be available for inspection by the FDA, the Sponsor or their 
designee, applicable foreign health authorities, and the IRB as appropriate. Subjects or their legal 
representatives may request their medical information be given to their personal physician or other 
appropriate medical personnel responsible for their welfare. 
Subject medical information obtained during the study is confidential and disclosure to third 
parties other than those noted above is prohibited. 
11.7 
Retention of Records 
To enable evaluations and/or audits from regulatory authorities or the Sponsor, the Investigator 
will keep records, including the identity of all participating subjects (sufficient information to link 
records, eg, eCRFs and hospital records), all original signed ICFs, copies of all eCRFs, SAE forms, 
source documents, and detailed records of treatment disposition. The records should be retained 
by the Investigator according to specifications in the ICH guidelines, local regulations, or as 
specified in the Clinical Study Agreement, whichever is longer. The Investigator must obtain 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 56 of 65 
Version 5.0, 19 December 2023 
written permission from the Sponsor before disposing of any records, even if retention 
requirements have been met. 
If the Investigator relocates, retires, or for any reason withdraws from the study, the Sponsor should 
be prospectively notified. The study records must be transferred to an acceptable designee, such 
as another Investigator, another institution, or to the Sponsor. 
11.8 
Publication Policy 
Following completion of the study, the data may be considered for publication in a scientific 
journal or for reporting at a scientific meeting. Each Investigator is obligated to keep data 
pertaining to the study confidential. The Investigator must consult with the Sponsor before any 
study data are submitted for publication. The Sponsor reserves the right to deny publication rights 
until mutual agreement on the content, format, interpretation of data in the manuscript, and journal 
selected for publication are achieved. 
11.9 
Financial Disclosure 
Investigators are required to provide financial disclosure information to the Sponsor to permit the 
Sponsor to fulfill its obligations under 21 CFR Part 54. In addition, Investigators must commit to 
promptly updating this information if any relevant changes occur during the study and for a period 
of 1 year after the completion of the study. 
11.10 
Insurance and Indemnity 
In accordance with the relevant national regulations, the Sponsor has taken out subject liability 
insurance for all subjects who have given their consent to the clinical study. This coverage is 
designed for the event that a fatality, physical injury, or damage to health occurs during the clinical 
study’s execution. 
11.11 
Legal Aspects 
The clinical study is submitted to the relevant national competent authorities in all participating 
countries to achieve a Clinical Trial Authorisation (CTA). 
The study will commence (ie, initiation of study centers) when the CTA and favorable Ethics 
opinion have been received.  

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 57 of 65 
Version 5.0, 19 December 2023 
12 
STUDY ADMINISTRATIVE INFORMATION 
12.1 
Protocol Amendments 
Any amendments to the study Protocol will be communicated to the Investigators by the Sponsor 
or designee. All Protocol Amendments will undergo the same review and approval process as the 
original Protocol. A Protocol Amendment may be implemented after it has been approved by the 
IRB, unless immediate implementation of the change is necessary for subject safety. In this case, 
the situation must be documented and reported to the IRB within 5 working days. 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 58 of 65 
Version 5.0, 19 December 2023 
13 
REFERENCES 
 
1. 
McShane PJ, Naureckas ET, Tino G, et al. Non-cystic ﬁbrosis bronchiectasis. Am J Respir 
Crit Care Med. 2013;188(6):647-656. 
2. 
Quint JK, Millett ERC, Joshi M, et al. Changes in the incidence, prevalence and mortality 
of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur 
Respir J. 2016;47(1):186-193. 
3. 
Hill AT, Routh C, Welham S. National BTS bronchiectasis audit 2012: is the quality 
standard being adhered to in adult secondary care? Thorax. 2014;69(3):292-294. 
4. 
Whitters D, Stockley R. Immunity and bacterial colonisation in bronchiectasis. Thorax. 
2012;67(11):1006-1013. 
5. 
Cullen L, McClean S. Bacterial adaptation during chronic respiratory infection. Pathogens. 
2015;4(1):66-89. 
6. 
Chalmers JD, Hill AT. Mechanisms of immune dysfunction and bacterial persistence in 
non-cystic ﬁbrosis bronchiectasis. Mol Immunol. 2013;55(1):27-34. 
7. 
Aliberti S, Lonni S, Dore S, et al. Clinical phenotypes in adult patients with bronchiectasis. 
Eur Respir J. 2016;47(4):1113-1122. 
8. 
Evans SA, Turner SM, Bosch BJ, et al. Lung function in bronchiectasis: the inﬂuence of 
Pseudomonas aeruginosa. Eur Respir J. 1996;9(8):1601-1604. 
9. 
Davies G, Wells AU, Doffman S, et al. The effect of Pseudomonas aeruginosa on 
pulmonary function in patients with bronchiectasis. Eur Respir J. 2006;28(5):974-979. 
10. 
Wilson CB, Jones PW, O’Leary CJ, et al. Effect of sputum bacteriology on the quality of 
life of patients with bronchiectasis. Eur Respir J. 1997;10(8):1754-1760. 
11. 
King PT, Holdsworth SR, Freezer NJ, et al. Microbiologic follow-up study in adult 
bronchiectasis. Respir Med. 2007;101(8):1633-1638. 
12. 
Martínez-García MA, Soler-Cataluña JJ, Perpiñá-Tordera M, et al. Factors associated with 
lung function decline in adult patients with stable non-cystic ﬁbrosis bronchiectasis. Chest. 
2007;132(5):1565-1572. 
13. 
Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin 
in patients with cystic ﬁbrosis. N Engl J Med. 1999;340(1):23-30. 
14. 
Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum 
Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med. 
2000;162(2 Pt 1):481-485. 
15. 
Hill AT, Bilton D, Brown J, et al. British thoracic society quality standards for clinically 
significant bronchiectasis in adults. British Thoracic Society Reports. 2012;4(1). 
16. 
Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines 
for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629. 
17. 
Clokie MR, Millard AD, Letarov AV, et al. Phages in nature. Bacteriophage. 
2011;1(1):31-45. 
18. 
Chan BK, Turner PE, Kim S, et al. Phage treatment of an aortic graft infected with 
Pseudomonas aeruginosa. Evol Med Public Health. 2018;2018(1):60-66. 
19. 
Bragg R, van der Westhuizen W, Lee JY, et al. Bacteriophages as potential treatment 
option for antibiotic resistant bacteria. Adv Exp Med Biol. 2014;807:97-110. 
 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 59 of 65 
Version 5.0, 19 December 2023 
 
20. 
Schooley RT, Biswas B, Gill JJ, et al. Development and use of personalized 
bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant 
Acinetobacter 
baumannii 
infection. 
Antimicrob 
Agents 
Chemother. 
2017;61(10):e00954-17. 
21. 
Dedrick RM, Guerrero-Bustamante CA, Garlena RA, et al. Engineered bacteriophages for 
treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat 
Med. 2019;25(5):730-733. 
22. 
Dissanayake U, Ukhanova M, Moye ZD, et al. Bacteriophages reduce pathogenic 
Escherichia coli counts in mice without distorting gut microbiota. Front Microbiol. 
2019;10:1984. 
23. 
Cieplak T, Soffer N, Sulakvelidze A, et al. A bacteriophage cocktail targeting Escherichia 
coli reduces E coli in simulated gut conditions, while preserving a non-targeted 
representative commensal normal microbiota. Gut Microbes. 2018;9(5):391-399. 
24. 
Denou E, Bruttin A, Barretto C, et al. T4 phages against Escherichia coli diarrhea: potential 
and problems. Virology. 2009;388(1):21-30. 
25. 
Parasion S, Kwiatek M, Gryko R, et al. Bacteriophages as an alternative strategy for 
fighting biofilm development. Pol J Microbiol. 2014;63(2):137-145. 
26. 
Harper DR, Parracho HMRT, Walker J, et al. Bacteriophages and biofilms. Antibiotics 
(Basel). 2014;3(3):270-284. 
27. 
Hisert KB, Heltshe SL, Pope C, et al. Restoring cystic fibrosis transmembrane conductance 
regulator function reduces airway bacteria and inflammation in people with cystic fibrosis 
and chronic lung infections. Am J Respir Crit Care Med. 2017;195(12):1617-1628. 
28. 
Miller MR, Crapo R, Hankinson J, et al. General considerations for lung function testing. 
Eur Respir J. 2005;26(1):153-161. 
29. 
Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. 
Eur Respir J. 2005;26(5):948-968. 
30. 
Wanger J, Clausen JL, Coates A, et al. Standardisation of the measurement of lung 
volumes. Eur Respir J. 2005;26(3):511-522. 
31. 
Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for 
the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 
2012;40(6):1324-1343. 
32. 
Graham BL, Steenbruggen I, Miller MR, et al. Standardization of spirometry 2019 update. 
An official American Thoracic Society and European Respiratory Society technical 
statement. Am J Respir Crit Care Med. 2019;200(8):e70-e88. 
33. 
Quittner AL, O'Donnell AE, Salathe MA, et al. Quality of Life Questionnaire 
Bronchiectasis: final psychometric analyses and determination of minimal important 
difference scores. Thorax. 2015;70(1):12-20. 
34. 
Birring SS, Prudon B, Carr AJ, et al. Development of a symptom specific health status 
measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax. 
2003;58(4):339-343.  
35. 
Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir 
Med. 1991;85 Suppl B:25-31; discussion 33-37. 
36. 
Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for 
chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis. 
1992;145(6):1321-1327. 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 60 of 65 
Version 4.0, 24 August 2023 
APPENDIX A: SCHEDULE OF ASSESSMENTS AND TIMING OF SAMPLE COLLECTION AND 
PROCEDURES FOR THE TREATMENT PERIOD 
 
Table 1. 
Schedule of Assessments 
Visit 
Screening Period 
Baseline 
Treatment Period 
Safety Follow-Up Period 
Early 
Termination 
Screening 
Baseline 
1 
2 
3 
4 
5 
6 
7/EOS 
ET 
Day 
-35 to -2 
-7 to -1 
1 
5 
10 
11 
17 
24 
38 
U 
Visit Window 
 
 
 
 
 
 
(±3d) 
(±3d) 
(±3d) 
 
Informed consenta 
X 
 
 
 
 
 
 
 
 
 
Inclusion/exclusion criteria 
X 
X 
Xb 
 
 
 
 
 
 
 
Demographic information 
X 
 
 
 
 
 
 
 
 
 
Medical/surgical history 
X 
 
 
 
 
 
 
 
 
 
Prior/concomitant 
medications 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
HIV antibody, HBsAg, and 
HCV by RNAc 
X 
 
 
 
 
 
 
 
 
 
Weight and heightc 
X 
 
 
 
 
 
 
 
 
 
Physical examinationd 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Vital signs and SpO2e 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Spirometryf 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
CT or HRCTg 
X 
 
 
 
 
 
 
 
 
 
Pregnancy testh 
X 
X 
 
 
 
 
 
 
X 
 
12-lead ECG 
X 
 
X 
 
 
 
 
 
X 
X 
Clinical laboratory 
assessmentsi 
X 
X 
X 
X 
X 
 
X 
X 
 
X 
Urinalysis 
X 
X 
 
X 
X 
 
 
 
 
X 
Induced sputum sample 
(required) 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
     Sputum culturek 
Xj 
X 
 
X 
X 
X 
X 
X 
X 
X 
     Sputum phage titerl 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
     Antipseudomonal 
antibiotic sensitivity 
X 
X 
 
 
 
 
 
X 
X 
X 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 61 of 65 
Version 4.0, 24 August 2023 
     Sensitivity of P. 
aeruginosa isolates to AP-
PA02 
X 
 
 
 
 
 
 
X 
X 
X 
     Biomarkers 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Expectorated sputum 
sample (if able to provide) 
 
* 
* 
* 
* 
* 
* 
* 
* 
* 
     Sputum culturek 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
     Sputum phage titer 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Blood phage titerm 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Urine phage titern 
 
X 
 
 
 
X 
 
 
 
X 
Randomization 
 
X 
 
 
 
 
 
 
 
 
Distribute sputum and urine 
collection containers 
 
 
X 
 
 
 
 
 
 
 
Daily symptom diary 
 
Dispense 
Review Review Review Review Review Review 
Collect 
Collect 
 
Table 1. 
Schedule of Assessments (Continued) 
Visit 
Screening Period 
Baseline 
Treatment Period 
Safety Follow-Up Period 
Early Termination 
Screening 
Baseline 
1 
2 
3 
4 
5 
6 
7/EOS 
ET 
Day 
-35 to -2 
-7 to -1 
1 
5 
10 
11 
17 
24 
38 
U 
Visit Window 
 
 
 
 
 
 
(±3d) 
(±3d) 
(±3d) 
 
Dispense study drug for home 
administrationo 
 
 
X 
X 
X 
 
 
 
 
 
Study drug administration 
training 
 
 
X 
 
 
 
 
 
 
 
Study drug administrationp 
 
 
X 
X 
X 
 
 
 
 
 
Antibiotic administrationq 
 
X 
X 
X 
X 
X 
X 
X 
 
 
QOL-B Questionnaire 
 
X 
 
 
 
X 
 
X 
 
 
LCQ 
 
X 
 
 
 
X 
 
X 
 
 
Saint George’s Respiratory 
Questionnaire 
 
X 
 
 
 
 
 
 
X 
 
Anti-phage antibody titer 
 
X 
 
 
 
 
 
X 
X 
X 
AEs/SAEsr 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Note: If a subject withdraws prematurely from the study, study staff should make every effort to complete the full panel of assessments scheduled for the ET Visit. See the Timing 
of Sample Collection and Procedures for the Treatment Period table for sample collection and procedure timing during the Treatment Period. The Treatment Period may be up to 
28 days for the optional cohorts. 
a. 
Signed informed consent must be obtained before any study-related procedures are performed. 
b. 
Any updates since the Baseline Visit will be assessed.  

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 62 of 65 
Version 4.0, 24 August 2023 
c. 
HIV antibody, HBsAg, and HCV antibody testing will be performed at Screening, only if status is unknown. Height will be collected at the Screening Visit only and will be 
used to calculate body mass index and percent predicted spirometry values by GLI standards. 
d. 
A full physical examination will be performed at the Screening Visit, Baseline Visit, and the EOS Visit. A symptom-directed physical examination will be performed at the 
other visits. 
e. 
Vital signs include blood pressure, heart rate, respiratory rate, and body temperature. 
f. 
FEV1, FVC, and FEF25-75 will be collected. Actual liter values will be recorded. Study eligibility will be based on percent predicted value using GLI standards, which requires 
race and ethnicity information as part of the GLI calculation. Spirometry will be collected prior to sputum induction on non-Treatment Period Visits. 
g. 
A CT or HRCT that demonstrates bronchiectasis per Inclusion Criterion 4 is required during the Screening Period unless such an examination has been performed within the 
last 5 years and meets the criteria in Inclusion Criterion 4. 
h. 
For women of childbearing potential only, a serum pregnancy test will be performed during the Screening Period and a urine pregnancy test will be performed at the other visits. 
i. 
Includes clinical chemistry, hematology, and coagulation. See Appendix B for a list of clinical laboratory analytes. Abnormal laboratory results during the Screening Period 
may be repeated once and only once at the discretion of the Investigator. Subjects with values outside the normal range may be permitted if the value is not clinically significant 
in the opinion of the Investigator with concurrence from the study Medical Monitor and/or Sponsor designee. 
j. 
Subjects must have microbiological evidence of pulmonary P. aeruginosa infection from a sputum sample within the last 24 months. Must have ≥104 CFU of P. aeruginosa per 
gram of induced sputum obtained at Screening or during the Screening Period. Sputum cultures may be repeated on up to 3 occasions during the Screening Period to document 
P. aeruginosa presence if the initial sputum culture is negative.  
k. 
Induced sputum samples for culture will be required at Screening, Baseline, Visit 2/Day 5, Visit 3/Day 10, Visit 4/Day 11, Visit 5/Day 17, Visit 6/Day 24, and Visit 7/EOS/Day 
38.  For expectorated sputum collection, subjects may be asked to provide first morning samples expectorated before a given clinic visit or the subjects may provide the 
expectorated sputum sample during the clinic visit. Samples collected at home by the subject should ideally be collected prior to administration of any inhaled antipseudomonal 
antibiotic. 
l. 
Induced sputum samples will be required on Visit 1/Day 1, Visit 2/Day 5, Visit 3/Day 10, Visit 4/Day 11, Visit 5/Day 17, Visit 6/Day 24, and Visit 7/EOS/Day 38. Sputum 
samples will be obtained in the morning on Visit 4/Day 11. 
m. When blood samples are scheduled at time points when safety laboratories and phage titer samples are also to be collected, safety laboratory samples are to be collected first, 
followed by phage titer samples. Blood samples will be obtained in the morning on Visit 4/Day 11. 
n. 
Date and time will be recorded for each urine sample collection at the designated time points. 
o. 
The subject will receive study drug doses for home administration on Visit 1/Day 1 for treatment Days 2 through 4 and on Visit 2/Day 5 for treatment Days 5 (second dose) 
through 9 and on Visit 3/Day 10 for treatment Day 10 (second dose). 
p. 
The first 2 subjects in Cohorts A and B will consist of 1 active and 1 placebo subject. Both subjects will be observed for at least 2 days after dosing and if there are no Grade 2 
or greater AEs assessed as treatment-related, dosing for the remaining subjects will proceed. Study drug will be administered as 1 fractionated dose of AP-PA02 or placebo 
(1 dose distributed over 2 administrations given 6 hours apart on the same day on Day 1 and 10-12 hours apart each day on the remaining days) for 10 consecutive days. Subjects 
will administer AP-PA02 or placebo at home on days they do not visit the clinic. AP-PA02 and placebo will be administered in the clinic during Visit 1/Day 1 (both doses), 
Visit 2/Day 5 (morning dose only), and Visit 3/Day 10 (morning dose only). 
q. 
The subject’s current antipseudomonal inhaled antibiotic will be administered at  Baseline, and for a total of 28 days, 10 days of study treatment and the following 18 days, for 
subjects in Cohort B only. 
r. 
Only SAEs will be recorded from Screening until the first dose of AP-PA02 or placebo. After the first dose of AP-PA02 or placebo all AEs will be recorded. 
AE = adverse event; CFU = colony-forming units; CT = computerized tomography; d = days; ECG = electrocardiogram; EOS = End of Study; ET = Early Termination; 
FEF25-75 = forced expiratory flow between 25% and 75% of the forced vital capacity; FEV1 = forced expiratory volume; FVC = forced vital capacity; GLI = Global Lung 
Initiative;HBsAg = hepatitis B surface antigen; HCV = hepatitis C virus; HIV = human immunodeficiency virus; HRCT = high-resolution computerized tomography; 
LCQ = Leicester Cough Questionnaire; QOL-B = Quality of Life-Bronchiectasis; RNA = ribonucleic acid; SAE = serious adverse event; SpO2 = oxygen saturation; U = Unscheduled. 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 63 of 65 
Version 4.0, 24 August 2023 
Table 2. 
Timing of Sample Collection and Procedures for the Treatment Period 
Visit 
Treatment Period 
1 
2 
3 
Day 
1 
5 
10 
Time 
Prior to 
first dose 
30 minutes 
after first dose 
1 hour 
after first 
dose 
1 hour after 
second dose 
Prior to 
first dose 
30 minutes 
after first dose 
Prior to 
first dose 
30 minutes 
after first dose 
1 hour after 
first dose 
Induced sputum 
sample (required) 
 
 
 
 
* 
* 
 
 
 
* 
     Sputum culture 
 
 
 
 
X 
 
 
 
X 
     Sputum phage 
titer 
 
 
 
X 
X 
 
 
 
X 
     Biomarkers 
 
 
 
X 
X 
 
 
 
X 
Expectorated 
sputum sample (if 
able to provide) 
 
 
 
 
* 
 
* 
 
 
     Sputum culture 
 
 
 
 
X 
 
X 
 
 
Blood phage titer 
 
 
 
X 
X 
 
 
 
X 
Urinalysis 
 
 
 
 
X 
 
X 
 
 
Vital signs and 
SpO2a 
X 
X 
 
X 
X 
X 
X 
X 
 
Spirometryb 
X 
 
 
X 
X 
 
X 
 
X 
12-lead ECG 
X 
 
X 
 
 
 
 
 
 
Clinical laboratory 
assessmentsc 
X 
 
 
 
X 
 
X 
 
 
a. 
Vital signs include blood pressure, heart rate, respiratory rate, and body temperature. 
b. 
FEV1, FVC, and FEF25-75 will be collected. Actual liter values will be recorded. 
c. 
Includes clinical chemistry, hematology, and coagulation. See Appendix B for a list of clinical laboratory analytes. 
d = days; ECG = electrocardiogram; EOS = End of Study; ET = Early Termination; FEF25-75 = forced expiratory flow between 25% and 75% of the forced vital capacity; 
FEV1 = forced expiratory volume; FVC = forced vital capacity; SpO2 = oxygen saturation. 
 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 64 of 65 
Version 4.0, 24 August 2023 
APPENDIX B: CLINICAL LABORATORY ANALYTES 
Standard Safety Chemistry Panel 
Alanine aminotransferase 
Albumin 
Alkaline phosphatase 
Amylase 
Aspartate aminotransferase 
Bicarbonate 
Blood urea nitrogen 
Calcium 
Chloride 
Creatine kinase 
Creatinine 
Creatinine clearance [1] 
Estimated glomerular filtration rate 
Gamma-glutamyl transferase 
Glucose 
Inorganic phosphorus 
Lactate dehydrogenase 
Lipase 
Potassium 
Sodium 
Total bilirubin 
Total protein 
Uric acid 
 
1. 
Creatinine clearance will be calculated using the Cockcroft-Gault equation based on actual body weight. 
 
Hematology 
Hematocrit 
Hemoglobin 
Platelets 
Red blood cell count 
White blood cell count and differential [1] 
 
1. 
Manual microscopic review is performed only if white blood cell count and/or differential values are out of reference range. 
 
Coagulation 
International Normalized Ratio 
 
 
Pregnancy Test 
Serum β-human chorionic gonadotropin [1] 
Urine β-human chorionic gonadotropin [1] 
1. 
For women of childbearing potential only, a serum pregnancy test will be performed during the Screening Period and a urine 
pregnancy test will be performed at the other visits. 
 
Urinalysis 
Bilirubin 
Blood 
Glucose 
Ketones 
Leukocyte esterase 
Microscopy [1] 
Nitrite 
pH 
Protein 
Specific gravity 
Urobilinogen 
 
1. 
Microscopy is performed only as needed based on abnormal dipstick test results. 
 

Armata Pharmaceuticals, Inc. 
Clinical Study Protocol AP-PA02-201 
Confidential & Proprietary 
Page 65 of 65 
Version 4.0, 24 August 2023 
Immunogenicity Test 
Anti-phage antibody titer 
Serology 
Hepatitis B surface antigen 
Hepatitis C virus by ribonucleic acid 
Human immunodeficiency virus antibody 
Biomarker Test 
Sputum neutrophil elastase